,PageNo,Text
0,page_0,"',6&/2685(  5('$&7('35272&2/$0(1'0(17   &&6362  $3+$6(08/7,&(17(55$1'20,=( '3/$&(%2&21 752//(''28%/(  %/,1'678'<2)7+(()),&$&<$1'6$) (7<2)$35(0,/$67 && ,1 68%-(&76:,7+02'(5$ 7(726(9(5(3/$48(3625,$6,62)7+(6&$/3  7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW \RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG   &HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFD OWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH JRDORIIXUWKHULQJVFLHQFHDQGHQKD QFLQJKHDOWKFDUHZRUOGZLGH /DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHU KDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RU UHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU YHQGRUV  7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFH UWDLQLQIRUPDWLRQKDVEHH QUHGDFWHGLQRUGHU WRFRPSO\ZLWKWKHDIRUHPHQWLR QHGREOLJDWLRQVRUWRSURWHFW&HO JHQHÂ¶VFRQILGHQWLDOFRPPHUFLDO LQIRUPDWLRQ7KHUHGDFWLRQV DUHEDVHGRQWKHIROORZLQJSULQFLS OHV   x5HGDFWHGLQIRUPDWLRQKDVEHHQU HSODFHGE\JUH\VSDFHPDLQWDLQL QJRULJLQDOVSDFLQJDQGSDJLQDWLRQ x$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGX DOVKDVEHHQUHGDFWHGIRU DQRQ\PL]DWLRQ x$WWDFKPHQWVWRWKLVUHSRUWWKDWF RQWDLQFRQILGHQWLDOLQIRUPDWLR QDUHQRWPDGHDYDLODEOH6XFK DWWDFKPHQWVLQFOXGHWKRVHWKDWF RQWDLQLGHQWLILDEOHSDWLHQWLQI RUPDWLRQVXFKDVVXEMHFWOLVWLQJV QDUUDWLYHVDQGSURILOHV7KH\ DOVRPD\FRQWDLQFRQILGHQWLDOF RPPHUFLDOLQIRUPDWLRQVXFKDV PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\V HV x&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWV VXFKDVOLQNVWRVXEMHFW OLVWLQJVLQ6HFWLRQ DUHQRW UHGDFWHGIURPWKHERG\RIWKHUHSRU W+RZHYHUWKHK\SHUOLQNV LQWKHHOHFWURQLFGRFXPHQWDUHQR ORQJHUIXQFWLRQDO x,QIRUPDWLRQDERXW&HOJHQHYHQGRU VDQGWKHLUVHUYLFHVDUHUHGDFW HGEHFDXVHPDQ\FRQWUDFWVSURKLELW GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQV SUHYHQWXVIURPGLVFORVLQJFHUWDLQ LQIRUPDWLRQDERXWRXUYHQGRUVRUWK HLUVHUYLFHVEHFDXVHLWLVS URWHFWHGE\FRS\ULJKW ,QIRUPDWLRQDERXW&HOJHQHÂ¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODEL OLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\ EHIRXQGDWKWWS ZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFD OWULDOVFOLQLFDOWULDOVGDWDVKDULQJ   &(/*(1(35235,(7$5<,1)250$7,21 ,11 &$/3$/3 EHVKDUHGREHVKDUHGR HUVDQGHUVDQGSDWLHSDWL XODWLRQVUHTXDWLRQV RUFRQWUDFWXRUFRQWUDFWX FHUWDLQSDUWFHUWDLQSD LQIRUPDWLRLQIRUPDW &HOJHQHÂ¶VFROJHQHÂ¶VF QFLSOHV QFLSOHV VSDFHVSDFHPDLQPDLQ DWLRQRILQGDWLRQRILQG FRQILGHQWLDORQILGHQWL QLGHQWLILDEQLGHQWLI RPD\PDFRQWDFRQWD JHQHUDWLQJJHQHUDWLQJ DFKPHQWV DFKPHQWV IWKHUHSRUWWKHUHSRUW &&HOJHQHYHQHOJHQHY WLQIRUPDWLRWLQIRUPDWLR ERXWRXUYHQERXWRXUYH DERXW&HOJDERXW&HOJ DWKWWS ZZKWWS Z"
1,page_1,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 1 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017TITLE PAGE A PHASE 3, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF APREMILAST (CC- 10004) IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS OF THE SCALP PROTOCOL NUMBER: CC-10004-SPSO-001 DATE FINAL: 29 Mar 2017 AMENDMENT 1 FINAL: 30 Nov 2017 EudraCT NUMBER: Not Applicable IND NUMBER: IND 070270 SPONSOR NAME/ ADDRESS: Celgene Corporation 86 Morris AvenueSummit, NJ 07901 CONFIDENTIAL This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by you, your staff, and ethics committee/institutional review board. The information contained in this document is regarded as confidential and, except to the extent necessary to obtain informed consent, may not be disclosed to another party unless such disclosure is required by law or regulations. Persons to whom the information is disclosed must be informed that the information is confidential and may not be further disclosed by them. CCI&(/*(1(11(35235,(7$5<,1)250$7,21lele 27070 ene Corporene Corpo 6 Morris A6 Morris A Summit, Summit, NFIDENTNFIDENT ou as an Inou as an I ou, your stou, you ormation cormation c cept to the eept to the e sed to anotsed to an ions. Persoions. P d that the inthat the in,(5,( (1"
2,page_2,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 2 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION Contact Information: Name: Title: Address: Celgene Corporation 86 Morris Avenue Summit, NJ 07901 Phone: E-mail: Note: The back-up 24-hour global emergency contact call center should only be used if you are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for emergency calls. Back-up 24-hour Global Emergency Contact Call Center: CCIPPD PPD PPD PPD PPD &(/*(1(35235,(7$5<,1)250$7,210$0$0$0$ 25)21 er should er should Medical MMedic enter: nter: $57$$5PP"
3,page_3,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 3 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE {See appended electronic signature page} Signature of Celgene Therapeutic Area Head dd mmm yyyy Printed Name of Celgene Therapeutic Area Head and Title By my signature, I indicate I have reviewed this protocol and find its content to be acceptable. CCIPPD &(/*(1(35235,(7$5<,1)250$7,210$0$ 25ts content toconten <,1<,1"
4,page_4,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 4 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE Signature of Site Principal Investigator dd mmm yyyy Printed Name of Site Principal Investigator Institution Name:_______________________________________ By my signature, I agree to personally supervise the conduct of this study at my study site and to ensure its conduct is in compliance with the protocol, informed consent, Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from Celgene representatives, the Declaratio n of Helsinki, International Council for Harmonisation (ICH) Good Clinical Practices Guidelines, and local regulations governing the conduct of clinical studies. CCI&(/*(1(35235,(7$7$7$5<,1)250$7,210$0$5000 s studys study at m atyy , informed nformed ocedures, inedures, i national nationa C nes, and locs, and lo 7$"
5,page_5,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 5 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE Signature of Coordinating Principal Investigator dd mmm yyyy Printed Name of Coordinating Principal Investigator By my signature, I agree the protocol has been written to comply with ICH Good Clinical Practices guidelines and agree to offer guidance throughout the study as needed. CCI&(/*(1(35235,(7$5<,1)250$7,210$0$0$0$0$0$0$ ICH GoodICH Good t the studyhe stu <,1<,1"
6,page_6,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 6 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017PROTOCOL SUMMARY Study Title A Phase 3, Multi-Center, Randomized, Placebo-Cont rolled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis of the Scalp Indication The indication is moderate to severe plaque psoriasis of the scalp. Objectives Primary Objective !To evaluate the clinical efficacy of apremilast 30 mg twice daily (BID) compared with placebo, in subjects with moderate to severe plaque psoriasis of the scalp, at Week 16 Secondary Objective(s) !To evaluate the safety and tolerability of apremilast 30 mg BID compared with placebo, in subjects with moderate to severe plaque psoriasis of the scalp. !To evaluate the effect of apremilast 30 mg BID compared with placebo on itch over the whole body caused by plaque psoriasis !To evaluate the effect of apremilast 30 mg BID compared with placebo on itch associated with plaque psoriasis of the scalp !To evaluate the onset of effect on itch over the whole body caused by plaque psoriasis with apremilast 30 mg BID compared with placebo !To evaluate the onset of effect on itch associated with plaque psoriasis of the scalp with apremilast 30 mg BID compared with placebo !To evaluate the effect of apremilast 30 mg BID compared with placebo on health- related quality of life (HRQoL) Study Design This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp. Approximately 300 subjects will be randomized 2:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks. Ra ndomization will be stratified by baseline Scalp Physician Global Assessment (ScPGA) score (m oderate [3], severe [4]) to ensure balance between treatment arms with respect to baseline severity of scalp psoriasis. !Subjects randomized to the apremilast 30 mg BID treatment group will receive apremilast 30 mg tablets orally twice daily for the first 16 weeks CCI&(/*(1(35235,(7$5<,1)250$7,21D) comD) com pareparemmm off the scalp the scalff mg BID comg BID c psoriasis opsoriasis o ff compared wompared w mg BID comg BID co e scalpscalp itch over thitch over t mmpared wipared wimm tii fect on itchfect on BID comD com papam ect of apremect of apre f lifelifeff (HRQ(HR multmulticenter,icenter, etyetyofofyy aprem apreff he scalp.he scalp. matelytely 300 300 yy BID or plBID or pl ysician Glosician Glo between treetween tre"
7,page_7,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 7 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017!Subjects randomized to the placebo treatment group will receive placebo tablets (identical in appearance to apremilast 30 mg tablets) orally twice daily for the first16 weeks !All subjects will receive apremilast 30 mg tablets orally twice daily after the Week 16 Visit through the end of the Apremilast Extension Phase of the study The study will consist of four phases: !Screening Phase â€“ up to 35 days !Double-blind Placebo-controlled Phase â€“ Weeks 0 to 16 Subjects will receive treatment with one of the following: âˆ€apremilast 30 mg tablets orally BID or âˆ€placebo tablets (identical in appearan ce to apremilast 30 mg tablets) orally BID !Apremilast Extension Phase â€“ Weeks 16 to 32 âˆ€All subjects will be switched to (or continue with) apremilast 30 mg BID at Week 16. All subjects will maintain this dosing through Week 32. !Observational Follow-up Phase âˆ€Four-week Post-treatment Observational Follow-up Phase for all subjects who complete the study or discontinue from the study early. After all subjects have completed the Week 16 Visit (or discontinued from the study), a Week 16 database lock will be performed; the primary data analysis will be conducted . However, unblinded data will only be made available to select Sponsor and Contract Research Organization (CRO) team members involved with analysis of the data . All other Sponsor, site, and CRO personnel directly involved with the conduct of the study, will remain blinded to treatment assignments until the final database lock at the conclusion of the study. At the end of the study, ie, when all subjects have also co mpleted (or have been di scontinued) the Apremilast Extension Phase (Weeks 16 to 32) and the Observational Follow-up Phase, the final analysis will be performed and a final Clinical Study Report will be generated. The study will be conducted in compliance wi th the International Council for Harmonisation (ICH) of Technical Requirements for Regist ration of Phar maceuticals for Human Use/G ood Clinical Practice (GCP) and applicable regulatory requirements. Study Population Adult subjects â‰¥ 18 years of age with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index [PASI] â‰¥ 12, and Body Surface Area [BSA] â‰¥ 10%, and Static Physician Global Assessment [sPGA] â‰¥ 3 [moderate or greater]) who also ha ve moderate to severe plaque psoriasis of the scalp (Scalp Physician Global Assessment â‰¥ 3 [moderate or greater], and Scalp Surface Area â‰¥ 20%, and having had an inadequate response or intolerance to at least one topical therapy [for example, potent or super potent topical corticosteroids, vitamin D analogs, and combination products] for plaque psoriasis of the scalp). CCICCI CCI CCI voolved witlved wi final databfinal datab ts have alsts have als 16 to to 32) an32) an al Clinical al Clinical onducted ionducted i ical Requirical Requir tice (GCP)tice (GCP) opulationulation lt subjects lt subjects â‰¥ everitverity yInInded35,(7$5<,1)250$7,21blets)blet orallyorall emilast milast 30 30 hrough Weough We Foollollow-w-up u m the studym the study isit (or discsit (or dis data analysidata analys owever, unowever, un OrganizatiOrganiz AssessmeAssessme sorisoriasas235"
8,page_8,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 8 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Length of Study The study is designed as a 32-week study with a four-week Post-treatment Observational Follow-up visit and consists of 4 phases as described above. Please refer to Section 3for details. The End of Trial is defined as either the date of the last visit of the last subject to complete the post-treatment follow-up, or the date of receipt of the last data point from the last subject that is required for primary, secondary and/or exploratory analysis, as pre-specified in the protocol, whichever is the later date. Study Treatments All IP will be provided in blister cards throughout the entire study. Apremilast will be provided as 10, 20, or 30 mg tablets by the study Sponsor, Celgene Corporation. Placebo will be provided as identically appearing 10, 20, or 30 mg tablets. Investigational product (IP) will be taken or ally twice daily, approximately 12 hours apart, without restriction of food or drink. To mitigate potential gastrointestinal (GI) side effects, dose titration will be implemented in the first week of this study and at Week 16 for subjects initially randomized to placebo when they switch to apremilast 30 mg BID treatment. During Week 0 (Days 1 to 7), subjects will be dispensed dose titration blister cards with 10, 20, and 30 mg apremilast tablets or identically appearing placebo tablets. The blister cards will contain all IP required for 4 weeks of treatment, with the first 7 days containing the titration supplies or matching placebo (see Table 4 : Treatment Schema for Dose Titration at Visit 2 [Week 0]) which details the titration supplies from Day 1 to Day 7 in the Placebo-controlled Treatment Phase. IP will be dispensed as indicated below: !Weeks 0 to 16: Double-blind, Placebo-controlled Treatment Phase: Apremilast 30 mg BID or placebo BID. âˆ€Week 0 to 1: subjects will be dose titrated as described above. !Weeks 16 to 32: Apremilast Extension Phase: Apremilast 30 mg BID. âˆ€Week 16 to 17: subjects will be dose titrated as described below. At Visit 2 (Week 0), subjects who meet entry criteria will be randomized using a permuted block randomization in parallel 2:1 to receive either apr emilast 30 mg BID or placebo, using a centralized Interactive Re sponse Technology (IRT). Starting at Week 16, all subjects will be switched to, or will continue with apremilast. Subjects originally randomized to placebo at Week 0 will be switched to apremilast 30 mg BID at Week 16 (see Table 5 Treatment Schema for Dose Titration at Visit 7 [Week 16]) which details the titration supplies from Day 1 to Day 7 in the Apremilast Extension Phase. Dose titration blister cards will be used for subjects switching from placebo to apremilast; dummy titration blister cards (dosing at 30 mg BID directly) will be used for subjects initially randomized to receive apremilast 30 mg BID. At all other visits during the Apremilast Extension Phase, all subjects will r eceive apremilast 30 mg tablets which are to be taken twice daily. Dose modifications are not permissible in this study. CCI&(/*titi/*(1(35235,(7$5<,1)250$7,21provided ovided be provie provi dedde hours aparhours apa GI) side efGI) side ef 16 for subj6 for s eatmatmentent. . ation blisteion bliste tablets. Thtablets. rst t 77daydays cs c hema for Dhema for ayay 1 to Day 1 to Dayyy d below: d below: ebobo--cocontntrolrol ill be dose l be dose milast Extenast Exten subjects wsubjects cts who mes who m eel l 2:1 to re2:1 to r ve Response Respon k 16k 16, all sub, all su domized todomized to see eeTableTable 55 on supplion suppli er cards wier cards w lister cards lister cards receive apeceive ap ubjectubject"
9,page_9,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 9 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Overview of Key Efficacy Assessments Primary Efficacy Assessment !Scalp Physician Global Assessment (ScPGA) Additional Efficacy Assessments !Subjectâ€™s Assessment of Whole Body Itch numeric rating scale (NRS) !Subjectâ€™s Assessment of Scalp Itch NRS !!! ! !Health-Related Quality of Life (HRQoL) questionnaires âˆ€Dermatology Life Quality Index (DLQI) âˆ€ Overview of Key Safety Assessments Safety assessments will include: !Adverse events (AE) !12-lead electrocardiograms (ECG) !Chest radiographs (CXR) !Physical examinations !Vital signs !Pregnancy tests for females of childbearing potential (FCBP) !Clinical laboratory tests Statistical Methods The study will randomize approximately 300 subjects in a 2:1 ratio to apremilast 30 mg BID or placebo arms stratified by baseline ScPGA scor e (moderate [3], severe [4]). With this sample size, a chi-square test at the 2-sided 0.05 significance level will have 90% power to detect a minimum treatment difference of 18% (38% for apremilast 30 mg BID versus 20% for placebo) between the two arms for proportions of subjects achieving ScPGA response at Week 16 (defined as ScPGA score of clear [0] or almost clear [1] with at least a 2 point reduction from baseline at Week 16). Analyses for efficacy endpoints will be mainly on the intent-to-treat (ITT ) population, defined as all randomized subjects. Statist ical comparisons will be made b etween the two treatment arms. CCICCI CCI CCI CCI CCI CCI &(/*(1ethodsthods ywillwil randorandol o armas sstratstra , a chi, a chi -squasqua minimum trminimum tr between between 1(35235,(7$5<females of emales offf toryryteststesyy,1)250$7,21 efinefin<,1 1(3(1("
10,page_10,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 10 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017All statist ical tests will be at the 2-sided 0.05 signi ficance level and the corresponding p-values and confidence intervals will be reported. The primary and secondary efficacy endpoints will be hierarchically ranked for testing in order to c ontrol the overall type I error rate in claiming statist ical signif icance at the 2-sided 0.05 significance level. The primary endpoint, the proportion of subjects who achieved ScPGA response at Week 16 between apremilast 30 mg BID and placebo, will be compared using Cochranâ€“Mantelâ€“Haenszel (CMH) test adjusted by stratification factors in randomization. Missing values at Week 16 will be imputed using the multiple imputation (MI) method as the primary analysis. Sensitivity analyses will be performed us ing the last observation carried forward (LOCF) method and the non-responder imputation (NRI) method. The binary secondary efficacy endpoints will be analyzed similarly as the primary endpoint. The analysis for the continuous secondary endpoint will be performed using the analysis of covariance (ANCOVA) model. The ANCOVA model will use the change from baseline as the dependent variable and will include treatment group and stratification factor as independent variables and the baseline value as a covariate variable. All efficacy endpoints will be summarized by study visit for both the Placebo-controlled Phase (Weeks 0 to 16) and Apremilast Extension Phase (Weeks 16 to 32). When appropriate, exploratory endpoints at Week 16 will also be analyzed using CMH or ANCOVA methods similar to the primary and secondary endpoints. The safety analyses will be performed using th e safety population defi ned as all subjects who received at least one dose of IP. Safety will be assessed by clinical review of all relevant parameters including treatment-emergent adverse ev ents (TEAEs), laboratory tests, vital signs, and electrocardiogram (ECG) measurements. Data from safety assessments will be summarized descriptively for the Placebo-controlled Phase (Weeks 0 to 16) and the Apremilast Exposure Period. Adverse events will be classified using the Medical Dictionary for Regulatory Activities (MedDRA) classification system. All TEAEs will be summarized by system organ class, preferred term, severity, and relationship to IP. TEAEs leading to death or to IP withdrawal and serious TEAEs will also be summarized and listed separately. CCI&(/*(1(35235,(7$5<,1)250$7,21he e e nalysis oalysis o f f baseline abaseline r as indepenas indepe PlPlaceboacebo --coc )..When aphen a CMH or ANMH o populopulatatioion dn ed byed b clinicclinicy events (TEevents (TE ata froata fro m m sa se (Weeks se (Weeks using the Musing the M TEAEs wilEAEs wil nship to IPship to IP marized andmarized an"
11,page_11,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 11 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017TABLE OF CONTENTS TITLE PAGE ..............................................................................................................................1 PROTOCOL SUMMARY ..........................................................................................................6 1. INTRODUC TION ..................................................................................................17 1.1. Disease Background ...............................................................................................17 1.2. Compound B ackground ..........................................................................................17 1.3. Ration ale ................................................................................................................18 1.3.1. Study Rationale and Purpos e ..................................................................................18 1.3.2. Rationale for the Study De sign ...............................................................................18 1.3.3. Rationale for Dose, Schedule and Regimen Selectio n .............................................19 1.3.4. Rationale for Choice of Compar ator....................................................................... 19 2. STUDY OBJECTIVES AND ENDPOINTS ...........................................................21 3. OVERALL STUDY DESIGN ................................................................................24 3.1. Overall Study Desi gn..............................................................................................24 3.2. Study Duration for Subj ects....................................................................................25 3.3. End of Trial ............................................................................................................25 4. STUDY POPULATION .........................................................................................26 4.1. Number of Subjects ................................................................................................26 4.2. Inclusion Criteri a ....................................................................................................26 4.3. Exclusion Criteri a...................................................................................................27 5. TABLE OF EVENTS.............................................................................................30 6. PROCEDURES......................................................................................................33 6.1. Screening Period.....................................................................................................33 6.2. Treatment Pe riod....................................................................................................34 6.2.1. End of Tr eatment....................................................................................................35 6.3. Follow-up Period ....................................................................................................36 6.4. Efficacy Assessments .............................................................................................37 6.5. Safety Assessments .................................................................................................39 6.7. Patient Repor ted Outco mes.....................................................................................42 6.8. Photogra phy...........................................................................................................43 CCICCI CCI&(/*(1(35235,(7$5<,1)250$7,2177 .......1818 ..................... 181 ......................... .......................... ......................... ........................... ...................... ................. ........................ .......................... ........................... ...................... ...................... ........................... NTSNTS ......... ES........... g Periodg Period .... ment Perioment Perio nd of Treand of Trea FoFollolloww EffiEff .5..5.,1) &CI"
12,page_12,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 12 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 20177. DESCRIPTION OF ST UDY TREATM ENTS........................................................44 7.1. Description of Investigational Product(s) ................................................................44 7.2. Treatment Administration and Schedule .................................................................47 7.3. Overdose ................................................................................................................47 7.4. Method of Treatment Assignment ...........................................................................47 7.5. Packaging and Labeling ..........................................................................................47 7.6. Investigational Product Accountability and Disposal ..............................................48 7.6.1. Record of Admin istratio n .......................................................................................48 7.7. Investigational Product Compliance ........................................................................48 8. CONCOMITANT MEDICATI ONS AND PROC EDURES ....................................49 8.1. Permitted Concomitant Med ications and P rocedure s...............................................49 8.2. Prohibited Concomitant Medications and Procedures ..............................................49 8.3. Required Concomitan t Medication..........................................................................50 9. STATISTICAL CONSIDERATIONS ....................................................................51 9.1. Overvi ew................................................................................................................51 9.2. Study Population Definitions ..................................................................................51 9.3. Sample Size and Po wer Consider ations ...................................................................51 9.4. Background and Demographic Characteristics ........................................................52 9.5. Subject Disposition .................................................................................................52 9.6. Efficacy Analysis ....................................................................................................52 9.6.1. Efficacy Evaluation for the Placebo-controlled Phase (Weeks 0 to 16) ....................52 9.6.1.1. Primary Efficacy Endpoi nt......................................................................................52 9.6.1.2. Secondary Eff icacy Endpoi nts ................................................................................53 9.6.1.3. Multiplicity Adjustment..........................................................................................54 9.6.1.4. Exploratory Endpoints ............................................................................................55 9.6.1.5. Subgroup Analysis ..................................................................................................55 9.6.2. Efficacy Evaluation â€“ Apremilast Extension Phase (Weeks 16 to 32) ......................55 9.7. Safety An alysis.......................................................................................................55 9.8. Interim An alysis .....................................................................................................56 9.9. Other T opics ...........................................................................................................56 9.9.1. Investigational Product Compliance (Tablets) .........................................................56 9.9.2. Concomitant Th erapy .............................................................................................56 CCICCI &(/*(EffiEff .7..7. 9.8..8.*(1(35235,(7$5<,1)250$7,2177 .......484 ..............484 ......................... .......................... .......................... .......................... .......................... .................. ......................... .......................... s......................... aracteristaracterist icic ....................... ................. or the Placeor the Place EndpointEndpoint ficacyficacy EndpEndpyy tyty AAyydjustmdjus oratoryoratory End Endyy ubgroup Aubgroup A /*("
13,page_13,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 13 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 20179.9.3. Steering Committee ................................................................................................56 9.9.4. Internal Celgene Safety Monitoring During the Apremilast Program: Role of the Safety Ma nagement Team .................................................................................57 10. ADVERSE EV ENTS ..............................................................................................58 10.1. Monitoring, Recording and Re porting of Advers e Even ts .......................................58 10.2. Evaluation of A dverse Events.................................................................................58 10.2.1. Se riousness............................................................................................................. 58 10.2.2. Severity/I ntensi ty....................................................................................................60 10.2.3. Caus ality ................................................................................................................60 10.2.4. Dur ation ................................................................................................................ .61 10.2.5. Action Taken .......................................................................................................... 61 10.2.6. Outco me................................................................................................................. 61 10.3. Abnormal Laborat ory Valu es..................................................................................61 10.4. Pregna ncy...............................................................................................................62 10.5. Reporting of Serious Adverse Ev ents...................................................................... 62 10.5.1. Safety Querie s ........................................................................................................ 63 10.6. Expedited Reporting of Adverse Events ..................................................................63 11. DISCONTINUATIONS .........................................................................................64 11.1. Treatment Discontinuation ......................................................................................64 11.2. Study Discont inuation ............................................................................................64 12. EMERGENCY PROCEDURES .............................................................................66 12.1. Emergency Contact .................................................................................................66 12.2. Emergency Identification of Investigational Products .............................................66 13. REGULATORY CONSIDERATIONS ...................................................................67 13.1. Good Clinical Practice ............................................................................................67 13.2. Inve stigator Responsibilities ...................................................................................67 13.3. Subject Information and Informed Consent .............................................................68 13.4. Confidentiality ........................................................................................................68 13.5. Protocol A mendments.............................................................................................68 13.6. Institutional Review Board/Independent Ethics Committee Review and Approval ................................................................................................................ 68 13.7. Ongoing Information for Institutional Review Board/ Ethics Co mmittee ................69 13.8. Termination of the St udy........................................................................................69 CCI&(/*(1(35235,(7$5<,1)250$7,21..5858 ............... 6060 .......................... 6 .................... .......................... ..................... .................... ............... ...................... ....................... ........................... ........................... .......................... ........................... EDURESDURES ........................ ntificatitificati on on TORY CONORY CO Clinical PraClinical Pra estestigator Rigator Subject InSubject In ConfiConfi .5. PP &13.6.3"
14,page_14,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 14 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 201714. DATA HANDLING AND RECORDKEEPING .....................................................70 14.1. Data/Docu ments .....................................................................................................70 14.2. Data Management ...................................................................................................70 14.3. Record Retention ....................................................................................................70 15. QUALITY CONTROL AND QUALITY ASSURANCE ........................................72 15.1. Study Monitoring and S ource Data Veri ficatio n......................................................72 15.2. Audits and Inspections............................................................................................72 16. PUBLICATIONS ...................................................................................................73 17. REFERENCES.......................................................................................................74 18. APPENDICES ........................................................................................................76 Appendix A: Table of Abbreviations ......................................................................................76 Appendix B: Scalp Physician Global Assessmen t (ScPGA) ....................................................79 Appendix C: Modified Whole Body Itch Numeric Rating Scale (NRS) ..................................80 Appendix D: Scalp Itch Nume ric Rating S cale (NRS ).............................................................81 Appendix F: The Dermatology Li fe Quality Inde x (DLQ I)..................................................... 84 Appendix K: Treatment Sch ema for Dose Titration at Bas eline ..............................................94 Appendix L: Treatment Schema for Dose Titration at Week 16 .............................................. 95 Appendix M: Titration Blis ter Card Confi guration ..................................................................96 Appendix N: Active Treatment Blister Card Configuration .....................................................97 Appendix O: Placebo Treatment B lister Card Confi gurati on................................................... 98 CCICCI CCI &(/*(1(3523for Dose Tr Dose T35,(7$5DLQI)DLQI) ..........5<,1)250$7,2122 .......727 ..............737 ......................... .......................... .......................... .......................... NRS)NRS) .......... .................. ema for Doma for D Blister CardBlister Card e Treatmente Treatme acebo Treaacebo Trea$5< (7$5,(735,235"
15,page_15,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 15 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017LIST OF TABLES Table 1: Study Objectives .....................................................................................................21 Table 2: Study Endpoints .....................................................................................................22 Table 3: Table of Events.......................................................................................................30 Table 4: Treatment Schema for Dose Titr ation at Visit 2 (Week 0)....................................... 45 Table 5: Treatment Schema for Dose Titr ation at Visit 7 (Week 16).....................................46 Table 6: Abbreviations and Specialist Terms ........................................................................76 CCI&(/*(1(35235,(7$5<,1)250$7,214646 ......7676"
16,page_16,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 16 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017LIST OF FIGURES Figure 1: Study Design ..........................................................................................................25 CCI&(/*(1(35235,(7$5<,1)250$7,21"
17,page_17,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 17 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 20171. INTRODUCTION 1.1. Disease Background Psoriasis is a chronic, immune-mediated disorder. Plaque psoriasis, the most common form of psoriasis, is typically characterized by raised, demarcated erythematous plaques covered by a silvery scale ( Lebwohl, 2003a ). The scalp is the most frequent area affected by plaque psoriasis, occurring in up to 80% of patients ( van de Kerkhof, 1998 ). These lesions can affect the hair- bearing areas of the scalp, extending past the hair line, as well as in the retroauricular area and on the neck. The lesions and associated flaking can be visible as well as highly pruritic, causing a negative impact on the patientâ€™s quality of life ( Kragballe, 2013; Szepietowski, 2016 ). The presence of scalp hair makes application of topical therapies or use of phototherapy difficult and inconvenient, limiting their effectiveness as well as compliance ( Warren, 2008; Feldman, 2003 ). Currently approved topical corticosteroids and calcipotriene preparations may be limited by short treatment durations and poor treatment compliance. In addition, potent topical corticosteroid therapies can be associated with side effects such as tachyphylaxis, skin atrophy, striae, telangiectasia, and hypothalamic-pitui tary-adrenal (HPA) axis suppression ( van der Vleuten , 2001 ; Hogan, 1989 ). Other topical therapies, such as coal tar and anthralin preparations have cosmetically unappealing formulations, foul odor, limited efficacy, and potential carcinogenic risk ( Chan, 2009 ). Second-line therapies such as phototherapy and systemic medications have been used, however, safety and efficacy d ata from c ontrolled clinical trials for these agents is limited ( Chan, 2009 ). Efficacy data from controlled clinical trials involving treatment with biologics, such as ixekizumab has only recently been published ( Reich, 2016 ). Thus, there remains an unmet medical need in treating plaque psoriasis of the scalp, particularly in patients with moderate to severe plaque psoriasis of the scalp. 1.2. Compound Background Apremilast (CC-10004) is a specific phosphodiesterase type 4 (PDE4) inhibitor under development for use in the treatment of inflammat ory conditions. PDE4 is one of the major phosphodiesterases expressed in leukocytes. PDE4 inhibition by apremilast elevates cyclic adenosine monophosphate (cAMP) levels in immune cells, which in turn down-regulates the inflammatory response by reducing the expression of pro-inflammatory mediators such as tumor necrosing factor (TNF)- Î±, interleukin (IL)-23, IL-17, and other inflammatory cytokines, and increasing the production of anti-inflammatory mediators. In completed Phase 3 studies in subjects with m oderate to severe plaque psoriasis and active psoriatic arthritis, treatment with apremilast was associated with statistically significant and clinically meaningful improvements in multiple efficacy measures. On the basis of these studies, apremilast (OTEZLA Â®) is approved in approximately forty countries worldwide for the treatment of adult patients with active psoriatic arthritis and the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Apremilast remains under further clinical development for the treatment of inflammatory/ autoimmune disorders including BehÃ§etâ€™s disease, and ulcerative colitis. Further studies within the approved indications of plaque psorias is and psoriatic art hritis are also ongoing. CCI&(/*(1(35235,(7$5<,1)250$7,21on on ng a g a apyapydifficudifficuy 8;;FeldmanFeldman ns may be ls may be otent topicaotent topic phhylaxis, skylaxi suppressiosuppressio l tar and antar and a efficacyeffica , an as phototheas phototh data fata fromromfffm m m controllecontrolle lylyrecently recentlyy ating ating plaquaq riasis of theasis of th d phosphodiphospho ment of inflaent of inf in leukocyn leukocy t (cAMP) levcAMP) le y reducingy reducin )-)-Î±, Î±, intinerle duction of auction of a Phase 3 studhase 3 st hrithritis, treatis, treat y meaningfueaning milmilast (OTEast (OTE aduldult patit patil enen severe plaqevere plaq Apremprem"
18,page_18,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 18 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Please refer to the Investigatorâ€™s Brochure (IB) for detailed information concerning the available pharmacology, toxicology , drug metabolism, clinical studies, and adverse event profile of the investigational product (IP). 1.3. Rationale 1.3.1. Study Rationale and Purpose Plaque psoriasis of the scalp is often challenging to treat. Scalp skin is also relatively inaccessible, making topical therapies difficult to apply and inconvenient to use ( Ortonne, 2009 ). Given the visibility of the lesions and the scaling/ flaking as well as the itch associated with the disease, patients with plaque psoriasis of the scalp often experience considerable physical, psychological and social impacts to quality of life. There remains an unmet medical need in treating p laque psoriasis of the scalp as currently approved topical corticosteroids and calcipotriene preparations may be limited by short treatment durations, poor treatment compliance, limited efficacy, and cosmetic appeal. As well, potent topical corticosteroid therapies can be associated with side effects such as tachyphylaxis, skin atrophy, striae, telangiectasia, and hypothalamic-pitui tary-adrenal (HPA) axis suppression. Other topical therapies, such as coal tar and anthralin preparations, have the additional risk of carcinogenesis. Second-line therapies for plaque psoriasis of the scalp include phototherapy and systemic medications, however safety and efficacy data from controlled clinical trials for most of these agents is limited. Efficacy data from controlled clinical trials involving treatment with biologics, such as ixekizumab has only recently been published. Apremilast (CC-10004) is a specific phosphodiesterase type 4 (PDE4) inhibitor approved for the treatment of both psoriasis and psoriatic arthriti s. In Phase 2 and Phase 3 trials, apremilast demonstrated efficacy in treating subjects with moderate to severe plaque psoriasis. Furthermore, exploratory analyses performed in these studies showed that apremilast also provided si gnificant benefit in the treatment of moderate to severe plaque psoriasis of the scalp. This study is intended to directly assess the sa fety and efficacy of apremilast 30 mg twice daily (BID) in the treatment of subjects with moderate to severe plaque psoriasis of the scalp. 1.3.2. Rationale for the Study Design Exploratory analyses from the two pivotal Phase 3 studies of apremilast in subjects with moderate to severe plaque psoriasis (Study PSOR-008 and Study PSOR-009) demonstrated that apremilast 30 mg BID provided a treatment benefi t in the subset of subjects who also presented with plaque psoriasis of the scalp of moderate or greater severity at baseline using a six-point Scalp Physician Global Assessment (ScPGA). The 6-point ScPGA scale ranged from 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), to 5 (very severe). This study will directly investigate the safe ty and efficacy of apremilast 30 mg BID, compared with placebo, in the treatment of subjects with mode rate to severe plaque psoriasis of the scalp. The primary endpoint will be the proportion of subjects who achieved ScPGA response at Week 16 (defined as ScPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline at Week 16), based on th e intent-to-treat (ITT ) population. Based on Health Authority feedback, this study will us e a 5-point ScPGA scale ranging from 0 (clear), 1 (almost clea r), 2 (mild), 3 (moderate), to 4 (severe), instead of the 6-point scale used in prior CCI&(/*(1(35235,(7$5<,1)250$7,21009009)). hh the the hh cal, cal, s currents current ly ed by shorted by sho eal. As welal. As wel h as tachyphas tachyp HPA) PA) axis saxis e the addithe addit i the scalp inthe scalp m controllem contro inical trialsinical tria published.published. sterase tyterase ty pepy tis. In Phas. In Pha with moith mo derde rmrmed in theed in atment of matment assess the assess the ects with mects with m the Sthe S tudytu s from the from the t e plaque pse plaque ps mmg BID g BID mm prop psoripsori asis oasis o ysician Glocian Glo nimal), 2 (mnimal), 2 (m his studyhis study wwyy wiwithi plplhaceace he prihe pr"
19,page_19,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 19 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017studies. This modified 5-point ScPGA scale is static, limited in the number of categories, and has categorical descriptions that are distinct and non-overlapping. The primary endpoint will be assessed at Week 16 as results from prior studies suggest that a treatment effect over placebo can be demonstrated by this time point. The use of placebo for 16 weeks has been acceptable in moderate to severe plaque psoriasis clinical trials. A total treatment duration of 32 weeks was selected in order to assess longer term effect of apremilast in the treatment of moderate to severe scalp psoriasis. The study will also investigate the efficacy of apremilast 30 mg BID, compared with placebo, in the improvement of itch. The data from the two pivotal Phase 3 studies of apremilast in subjects with moderate to severe plaque psoriasis (Study PSOR-008 and Study PSOR-009) demonstrated improvement in itch severity using a Visual An alog Scale (VAS). In this study, improvement of itch will be assessed using Numeric Rating Scales (NRS) as these are considered to have better reliability and precision, and lesser potenti al for missing values, than the VAS ( Phan, 2012 ). The first secondary endpoint will be the proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the Whole Body Itch NRS score at Week 16. It is anticipated that approximately 80% of the subjects would be evaluable for this analysis, based on prior experience in Studies PSOR-008 and PSOR-009 as well as other clinical trials in moderate to severe plaque psoriasis ( Griffiths, 2015 ). Eligible subjects will be randomized 2:1 to receive either apremilast 30 mg BID or placebo in order to reduce exposure to placebo without gr eatly increasing num bers of subjects exposed to IP, while maintaining the statistical power of the study. Randomization will be stratified by baseline ScPGA score in order to ensure balance between treatment arms with respect to baseline severity of scalp psoriasis. 1.3.3. Rationale for Dose, Schedule and Regimen Selection Exploratory analyses from the two pivotal Phase 3 studies (PSOR-008 and PSOR-009) demonstrated that apremilast 30 mg BID provided a treatment benefit in subjects with plaque psoriasis of the scalp of moderate or greater seve rity. This study will directly investigate the safety and efficacy of this dosing regimen in the treatment of subjects with moderate to severe plaque psoriasis of the scalp. 1.3.4. Rationale for Choice of Comparator A randomized, double-blind placebo-controlled design was chosen in order to measure the absolute treatment effect of apremilast 30 mg BID in moderate to severe plaque psoriasis of the scalp. The placebo-controlled design also minimizes subject and investigator bias in evaluating the efficacy and safety of apremilast in the selected patient population (Food and Drug Administration [ FDA] Guidance for Industry E10 ). CCICCI &(/*(1(35235,(7$5<,1)250$7,21inn ubjects bjects onstrated onstrated ovemovem ent ofent o to have betto have be (Phan, 2012Phan, 20 uctiucton on k 16. It is a16. It alysis, basealysis, bas nical trialscal tria remilast 30remilast 30 asing asing numbnumb yy. Ran Ran domdom tween treattween trea and ndRRegimegim otalalPhasePhasell 3 BID providBID prov e or greater or greate ing regimenng regim p.. for or CChoiceh ubleuble--blind blind ment effect oent effec placeboplacebo -conco acyand safeand safey nistratnistr ion [n [F &((&&"
20,page_20,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 20 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017 CCICCI &(/*(1(35235,(7$5<,1)250$7,21"
21,page_21,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 21 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 20172. STUDY OBJECTIVES AND ENDPOINTS Table 1: Study Objectives Primary Objective The primary objective of the study is to evaluate the clinical efficacy of apremilast 30 mg twice daily (BID) compared with placebo, in subjects with mode rate to severe plaque psoriasis of the scalp, at Week 16. Secondary Objective(s) The secondary objectives are: !To evaluate the safety and tolerability of apremilast 30 mg BID compared with placebo, in subjects with moderate to severe plaque psoriasis of the scalp. !To evaluate the effect of apremilast 30 mg BID compared with placebo on itch over the whole body caused by plaque psoriasis !To evaluate the effect of apremilast 30 mg BID compared with placebo on itch associated with plaque psoriasis of the scalp !To evaluate the onset of effect on itch over the whole body caused by plaque psoriasis with apremilast 30 mg BID compared with placebo !To evaluate the onset of effect on itch associated with plaque psoriasis of the scalp with apremilast 30 mg BID compared with placebo !To evaluate the effect of apremilast 30 mg BID compared with placebo on health-related quality of life Exploratory Objective(s) The exploratory objectives are: !To evaluate the effect of apremilast 30 mg BID compared to placebo on Dermatological Life Quality Index (DLQI) CCIC CI CCI &(/*(1(35235,(7$5<,1)250$7,21777$7bo, in o, in over the over the wh on on itchitchasso d by plaque d by plaqu ue ue psoriasispsorias pared with ppared with $7$7$7 (7 ffect of apreffect of apr (DLQI)DLQI),( (/35 523352 (1(*(1*(/*(/*"
22,page_22,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 22 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Table 2: Study Endpoints Endpoint Name Description Timeframe Primary Scalp Physician Global Assessment (ScPGA)Proportion of subjects with ScPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline at Week 16. Week 16 Secondary Itch Numeric Rating Scale (NRS) [whole body]Proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the whole body itch NRS score Week 16 Itch NRS (Scalp) Proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the scalp itch NRS score Week 16 Onset of effect on itch NRS (whole body)Proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the whole body itch NRS scoreBy Visit in Placebo-controlled Phase (Week 12, Week 8, Week 4, Week 2) Onset of effect on itch NRS (Scalp)Proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the scalp itch NRS scoreBy Visit in Placebo-controlled Phase (Week 12, Week 8, Week 4, Week 2) Dermatological Life Quality Index (DLQI)Change from baseline in DLQI total score Week 16 Exploratory ScPGA Proportion of subjects with ScPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline By Visit Itch NRS (whole body) Proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the whole body itch NRS scoreBy Visit in Apremilast Extension Phase Itch NRS (Scalp) Proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the scalp itch NRS scoreBy Visit in Apremilast Extension Phase CCICCI CCI$7 16160$ nt t hhNRS NRS By By VisVis PlacP PP)21) cts with cts with â‰¥4-4 ovement) frovement) fro e scalp e scalp itchitch5< ange from bange from b corore e ,( 352352222 h NRS (whoNRS (who( *(ItcIt*(*(*(23523"
23,page_23,"EDMS Doc. Number: Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 23 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Table 2: Study Endpoints (Continued) Endpoint Name Description Timeframe DLQI Change from baseline in DLQI total scoreWeeks 4, 8, 16 and 32 Safety Type, frequency, severity, and relationship of adverse events to IPDay 0 through end of Observational Follow-UpStudy duration CCICCI CCI &(/*(1(35235,(7$5<,1)250$7,217nd nd 77$7$7$7 )$ )))21) < 7$ 5,( 23 of adverse of advers IPDD232323 (3230$ 1)2,1 5< (7$(7 35,235"
24,page_24,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 24 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 20173. OVERALL STUDY DESIGN 3.1. Overall Study Design This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp. Approximately 300 subjects with moderate to seve re plaque psoriasis of the scalp will be randomized 2:1 to r eceive either apremilast 30 mg BID or placebo for the first 16 weeks. Randomization will be stratified by baseline Scalp Physician Global Assessment (ScPGA) score (moderate [3], severe [4]) to ensure balance between treatment arms with respect to baseline severity of scalp psoriasis. !Subjects randomized to the apremilast 30 mg BID treatment group will receive apremilast 30 mg tablets orally twice daily for the first 16 weeks !Subjects randomized to the placebo treatment group will receive placebo tablets (identical in appearance to apremilast 30 mg tablets) orally twice daily for the first 16 weeks !All subjects will receive apremilast 30 mg tablets orally twice daily after the Week 16 Visit through the end of the Apremilast Extension Phase of the study The study will consist of four phases: !Screening Phase â€“ up to 35 days !Double-blind Placebo-controlled Phase â€“ Weeks 0 to 16 Subjects will receive treatment with one of the following: !apremilast 30 mg tablets orally BID or !placebo tablets (identical in appearan ce to apremilast 30 mg tablets) orally BID !Apremilast Extension Phase â€“ Weeks 16 to 32 !All subjects will be switched to (or continue with) apremilast 30 mg BID at Week 16. All subjects will maintain this dosing through Week 32. !Observational Follow-up Phase !Four-week Post-treatment Observational Follow-up Phase for all subjects who complete the study or discontinue from the study early. After all subjects have completed the Week 16 Visit (or discontinued from the study), a Week 16 database lock will be performed; the primary data analysis will be conducted . However, unblinded data will only be made available to select Sponsor and Contract Research Orga nization (CRO) team member s involved with analysis of the data . All other Sponsor, site, and CRO personnel directly involved with the conduct of the study, will remain blinded to treatment assignments until the final database lock at the conclusion of the study. At the end of the study, after all sub jects have completed, or have been discontinued from the Apremilast CCICCI CCI CCIo selo sel(/*(1(35235,(7$5<,1)250$7,21 score score eline ne will receive will receive ive placebove plac y twice dailytwice dail rallyrally twitwyy ce nnPhase of Phase of ase ase â€“â€“WeeWee with one ofwith one o s orally BIDs orally BI nticalciln apn ap ioionnPhase Phase ts will be swts will b 16. All sub16. All s vational Fovational Fo FourFour -wewe comcomppmmm all subjectsall subject tabase lockbase lock ectec l&(CI"
25,page_25,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 25 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Extension Phase (Weeks 16 to 32) and the Observational Follow-up Phase, the final analysis will be performed and a final Clinical Study Report will be generated. Figure 1: Study Design Abbreviation: BID = twice daily. The study will be conducted in compliance wi th the International Council for Harmonisation (ICH) of Technical Requirements for Registr ation of Pharmaceu ticals for Human Use/G ood Clinical Practice (GCP) and applicable regulatory requirements. 3.2. Study Duration for Subjects Subjects who complete the entire study will spe nd a total of approximately 41 weeks in this clinical trial: !Up to 35 days (5 weeks) in the Screening Phase !Weeks 0 to 16 (16 weeks) in the Double-blind Placebo-controlled Phase !Weeks 16 to 32 (16 weeks) in the Apremilast Extension Phase !Four-week (4 weeks) Post-treatment Observational Follow-up Phase 3.3. End of Trial The End of Trial is defined as either the date of the last visit of the last subject to complete the post-treatment follow-up, or the date of receipt of the last data point from the last subject that is required for primary, secondary and/or exploratory analysis, as pre-specified in the protocol, whichever is the later date. CCI&(/*(1(35235,(7$5<,1)250$7,212250250 ternationalternationa of Pharmacof Pharma ryyrequirequiy remrei ects ects yywillwilly spen spenll eeks) in theeks) in the (16 weeks)6 weeks) o o 32 (32 (16 w6 w week (4 weeeek (4 wee End of TrEnd of Tr d of Trial isd of Trial i treatmreatm ent fnt quiquired fred iii or por pfff whicheverwhichever"
26,page_26,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 26 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 20174. STUDY POPULATION 4.1. Number of Subjects Approximately 300 subjects with moderate to severe plaque psoriasis of the scalp will be enrolled and randomized from investig ator sites in Canada and the USA. 4.2. Inclusion Criteria Subjects must satisfy the following criteria to be enrolled in the study: 1. Males or females, â‰¥ 18 years of age at the time of signing the informed consent document 2. Understand and voluntarily sign an informed consent form (ICF) prior to any study- related assessments/procedures being conducted. 3. Be willing and able to adhere to the study visit schedule and other protocol requirements. 4. Have a diagnosis of moderate to severe plaque psoriasis of the scalp at screening and baseline as defined by: a. ScPGA (See Appendix B ) score of â‰¥3 (moderate or severe) and, b. Scalp Surface Area ( SSA) involvement of â‰¥20% and, c. Inadequate response or intolerance to at least one topical therapy (for example, potent or super potent topical corticosteroids, vitamin D analogs, and combination products) for plaque psoriasis of the scalp. 5. Must be a candidate for phototherapy and/or systemic therapy for either body or scalp psoriasis lesions. 6. Have moderate to severe plaque psorias is at screening and baseline as defined by: a. Psoriasis Area and Severity Index (PASI) ( ) score â‰¥12 and, b. Body Surface Area (BSA) â‰¥10% and, c. Static Physician Global Assessment (sPGA) ( ) â‰¥3 (moderate) 7. Must be in good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination, 12- lead electrocardiogram (ECG), clinical laboratories, and urinalysis 8. Must meet the following laboratory criteria a. White blood cell count #3000/mm3(#3.0 x 109/L) and < 14,000/mm3(< 14 x 109/L) b. Platelet count #100,000/Î¼L (#100 x 109/L) c. Serum creatinine âˆƒ1.5 mg/dL ( âˆƒ132.6 Î¼mol/L) d. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) âˆƒ2 x upper limit of normal (ULN) e. Total bilirubin â‰¤ 2 mg/dL (34 Î¼mol/L) f. Hemoglobin â‰¥ 9 g/dL (â‰¥ 5.6 mmol/L) CCICCI CCI &(/*(1(ryry(35235,(7$5<,1)250$7,21ocumentcument studystudy -- tocol requirtocol requi alp at slp at s creencreen r severesevere ) an) a % and,% and, ast one topiast one top roids, vitamroids, vitam scalp.scalp. d/or systemd/or system psoripsori asis at asis at veriveritytyiii Inde Inyy ea (ea (BSABSA )â‰¥)â‰¥ iananGlGlobal Aob health (exchealth (e , physical, physic s, and urinas, and urina meet the foleet the fo a.a.WhiteWhite 101099 b.b."
27,page_27,"EDMS Doc. Number: Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 27 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017g. Hemoglobin A1c âˆƒ9.0% 9. Females of childbearing potential (FCBP)â€ must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive Â§options described below: Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partnerâ€™s vasectomy; OR Option 2: Male or f emale condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide. 4.3. Exclusion Criteria The presence of any of the following will exclude a subject from enrollment: 1. Other than psoriasis, history of any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, ne urologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease. 2. Any condition, including the presence of laboratory a bnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study. 3. Any condition that confounds the ab ility to interpret data from the study. 4. Pregnant or breast feeding5. Hepatitis B surface antigen positive at Screening 6. Anti-hepatitis C antibody positive at Screening 7. AST (SGOT) and/or ALT (SGPT) > 1.5 X ULN andtotal bilirubin > ULN and/or albumin < lower limit of normal (LLN) 8. Active tuberculosis (TB) or a history of incompletely treated TB â€ A female of childbearing potential is a sexually mature female who 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been postmenopausal for at least 24 consecutive months (that is, has had menses at any time during the preceding 24 consecutive months). Â§The female subjectâ€™s chosen form of contraception must be effective by the time the female subject is randomized into the study (for example, hormonal contraception should be initiated at least 28 days before randomization). CCI&(/*(1(35235,(7$5<,1)250$7,21omomNOT mNOT mm PLUS one LUS on ) cervical c) cervical m m enrollmeenr icant (as deant (as d , neurolneurol ogio major unconmajor uncon laboratoryaboratory ay were to partiwere to part bilitbility y to into in n positive an positive odyodyposiposiyy titiiiivv /or ALT (S/or ALT er limit of nr limit of n erculosis (Trculosis (T *(of childbearchildbea l removal of removal of tmenopausamenopausa consecutive monsecutive"
28,page_28,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 28 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 20179. Clinically significant abnormality on 12-lead ECG at screening 10. Clinically significant abnormality based upon chest radiograph with at least a posterior to anterior (PA) view (radiograph must be taken within 12 weeks prior to screening or during the Screening Visit). An addition al lateral view is strongly recommended but not required. 11. History of positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease) 12. Active substance abuse or a history of subs tance abuse within 6 months prior to signing the informed consent form. 13. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of signing the informed consent form. Any treatment for such infections must have been completed at least 4 weeks prior to randomization. 14. Malignancy or history of malignancy, except for: a. treated (ie, cured) basal cell or squamous cell in situ skin carcinomas; b. treated (ie, cured) cervical intraepithelial neoplasia (CIN) or carcinoma in situ of the cervix with no evidence of recurrence within 5 years of signing the informed consent. 15. Prior history of suicide attempt at any time in the subjectâ€™s life time prior to signing the informed consent and randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent. 16. Psoriasis flare/rebound (defined as a sudden worsening of body plaque psoriasis or plaque psoriasis of the scalp which requires administration of prohibited medications) within 4 weeks of signing the informed consent form or between the Screening and Baseline Visits. 17. Current or planned concurrent use of the following therapies that may have a possible effect on psoriasis of the body and/or s calp during the course of the treatment phase of the trial: a. Topical therapy, including medicated shampoos, coal tar and salicylic acid preparations, within 2 weeks prior to randomization (including but not limited to topical corticosteroids, topical retinoid or vitamin D analog preparations, tacrolimus, pimecrolimus, or anthralin/dithranol). i. Exceptions: 1. non-medicated shampoos for scalp lesions2. unmedicated emollients for body lesions b. Conventional systemic therapy for psoriasis within 4 weeks prior to randomization (including but not limited to cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, or fumaric acid esters). CCI&(/*(1(35235,(7$5<,1)250$7,21ing ng significant ignificant oormrm. Any. Any s prior to prior to kin carcinoin carcino iaia(CIN) (C or hin 5 years hin 5 year the subjectthe subjec ajor psychiajor psychi or to sir to si gningnin sudden wosudden wo h requires h requires informed conformed co current use urrent use ththe bodye body ay alal therapy, therapyll paratiparati ons, wons, topitopicacal cortl c tacrolimtacrolim"
29,page_29,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 29 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017c. Intralesional corticosteroids on the scalp within 2 weeks prior to randomization d. Phototherapy treatment of body or scalp psor iasis lesions within 4 weeks prior to randomization (ie, ultraviolet B (UVB), psoralen and ultravio let A radiation [PUVA]) e. Biologic therapy: i. TNF or IL-17 blockers such as adalimumab, brodalumab, certolizumab pegol, etanercept, infliximab, ixek izumab, secukinumab (or biosimilars for each) within 12 weeks prior to randomization ii. Anti-IL-12 or anti-IL-23 monoclonal antibodies such as ustekinumab, guselkumab, or tildrakizumab, within 24 weeks prior to randomization f. Use of any investigational drug beginning 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer) 18. Evidence of scalp and/or skin conditions that would interfere with clinical assessments19. Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources 20. Prior treatment with apremilast 21. History of allergy or hypersensitivity to any components of the IP CCIor or mab, ab, mizationmization mization, ormization, or hever is lover is lo n clinical asslinical ass vioviolet (UVlet (UV nts of the IPnts of the"
30,page_30,"EDMS Doc. Number: Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 30 CC-10004-SPSO-001 Amendment 1 Final: 30 Nov 20175. TABLE OF EVENTS Table 3: Table of Events Screening Placebo-controlled Treatment Phase Apremilast Extension PhaseObservational Follow-up Visit Number 1Baselinea 2 3 4 5 6 7 8 9 10/ETb11 Week -5 to 00 (Day 1)2 (Â± 4 days)4 (Â± 4 days)8 (Â± 4 days)12 (Â± 4 days)16 (Â±4 days)20 (Â± 4 days)24 (Â±4 days)32 (Â±4 days)4 Weeks After Last Dose (Â± 2 weeks)c Administrative/Demographics Informed ConsentdX- - - - - - - - - - Demographics X - - - - - - - - - - Inclusion / Exclusion X X - - - - - - - - - Medical and Disease History X - - - - - - - - - - Prior / Concomitant Medications and TherapiesXXXX X XXX X X X Safety Assessment(s) Height, BMI X - - - - - - - - - - CXReX- - - - - - - - - - Hepatitis B and C, TBfX- - - - - - - - - - Hemoglobin A1C X - - - - - - - - - - Weight X X - - X - X - X X X Complete Physical Exam X - - - - - - - X - Vital Signs X X X X X X X X X X X Pregnancy Test for FCBP and Contraception EducationgXX - - - - - - - X - 12-lead ECG X - - - - - - - - - - Clinical Laboratory EvaluationshXX - - - -X - - X - CCI&(/*(priprietet(1(35235,(7$5<,1)250$7,21e Corporae Corpora 21 milast Extensmilast Exten0$ 8825252525 days)days)202 (Â± (Â±44)222 12 ,111 -<<<5<--5<5<5<5<--$555 75 --777$(7XX(7(7(75(7555, --35353535--233 523 523 --52525252--35555 --3(--((((XX1((( (( XX(((1*(XX***/*nsnshhXX///*(/(/(/(/"
31,page_31,"EDMS Doc. Number: Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 31 CC-10004-SPSO-001 Amendment 1 Final: 30 Nov 2017Table 3: Table of Events (Continued) Screening Placebo-controlled Treatment Phase Apremilast Extension PhaseObservational Follow-up Visit Number 1Baselinea 2 34 5 6 78 9 1 0 / E Tb11 Week -5 to 00 (Day 1)2 (Â± 4 days)4 (Â± 4 days)8 (Â± 4 days)12 (Â± 4 days)16 (Â±4 days)20 (Â± 4 days)24 (Â±4 days)32 (Â±4 days)4 Weeks After Last Dose (Â± 2 weeks)c Vasculitis Assessmenti---- - --- - - - Psychiatric Evaluationj---- - --- - - - Adverse Events X X X X X X X X X X X Psoriasis Flare Assessmentk---- - --- - - - Clinical Efficacy Assessment(s)l Whole Body Itch NRSm- XXX X X XX XX - Scalp Itch NRSm- XXX X X XX XX - ScPGA X X X X X X X X X X X Patient Reported Outcomes DLQI - X - X X - X - - X - CCICCI CCI CCI priprietet/*/**1(3X-(((3(35235,(7$5<,1)250$7,21e Corporae Corpora 21 nsion Phasesion Phase7,2222 990$0$0$0$ 4 days)4 da2424 (Â±4Â±455025--)222 12 --111)1XX,1111 -<,5<5<5<5<XX$555 75 XX777$7XX777$(7 5235,(7 (35 /*(1("
32,page_32,"EDMS Doc. Number: Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 32 CC-10004-SPSO-001 Amendment 1 Final: 30 Nov 2017Table 3: Table of Events (Continued) Screening Placebo-controlled Treatment Phase Apremilast Extension PhaseObservational Follow-up Visit Number 1Baselinea 2 34 5 6 78 9 1 0 / E Tb11 Week -5 to 00 (Day 1)2 (Â± 4 days)4 (Â± 4 days)8 (Â± 4 days)12 (Â± 4 days)16 (Â±4 days)20 (Â± 4 days)24 (Â±4 days)32 (Â±4 days)4 Weeks After Last Dose (Â± 2 weeks)c Optional Assessment(s) at Selected Investigative Sites Photographso-X- - X -X- - X - Dosing Dispense IP - X - X X X X X X - - Return and count IP tablets - - - X X X X X X X - Abbreviations: BMI = body mass index; ; CXR = Chest Radiograph; DLQI = The Dermatology Life Quality Index; ECG = Electrocardiogram ; ET = Early Termination Visit; FCBP = females of childbearing potential; IP = Investigational Product; NRS = Numeric Rating Scale; ; ScPGA = Scalp Physician Global Assessment; TB = tuberculosis testing; aAll baseline assessments must be completed prior to randomization and dispensing of IP. bVisit 10 will serve as the Early Termination Visit for any subject who prematurely discontinues from the study. cAll subjects who complete the study or discontinue the study early will be asked to enter the Four-week Post-treatment Observat ional Follow-up Phase. dWritten informed consent will be obtained by the Principal Investigator or designee prior to performing any study assessments. eCXRs taken within 12 weeks prior to screening will be accepted. CXRs should be performed as indicated by local treatment guide lines or practice for monitoring while on immunosuppressive/immunomodulatory therapy. If such guidelines are not available/applicable, routine CXRs should be performed as per the Table of Events or when clinically indicated. fThe QuantiFERONÂ®Gold test should be used for TB testing in lieu of the tuberculin skin test (TST) or purified protein derivative (PPD) test, if possible. gFCBP: Serum pregnancy tests will be performed at the Screening and Early Termination/Last Treatment Visit. Urine dipstick pre gnancy test(s) will be performed at baseline, prior to dosing. An unscheduled pregnancy test should be administered if the subject has missed a menstrual period. The Inves tigator will educate all FCBP about the options for and correct use of contraceptive methods at the Screening and Baseline Visits and at any time when a FCBPâ€™s contraceptive mea sures or ability to become pregnant changes. hRefer to Section 6.5, Procedures, for details regarding hematology, clinical chemistries, and urinalysis parameters to be tested. iAt any time vasculitis is suspected. See Section 6.5, Procedures jAt any time when suicidal thoughts or a suicide attempt is identified. See Section 6.5, Procedures kAt any time, a psoriasis flare may be reported as an adverse event, provided it meets the protocol definition. See Section 6.5, Procedures lClinician assessments are to be performed after subject completes numeric rating scales and patient reported outcomes questionn aires as scheduled in the Table of Events. Clinician assessments must be done in the following order: ScPGA, . mSubject assessment of whole body itch must be performed prior to scalp itch assessment. nSubject assessments must be completed in the following order: whole body itch NRS, scalp itch NRS, DLQI, as scheduled in the T able of Events. oPhotographs will be obtained from subjects who provide separate consent to be photographed and at select sites only. CCICCI CCI CCI CCI CCI CCI CCI CCI CCICCI &(/priprietet/*(1(35235,(7$= tuberculosi= tuberculosi f IP.f IP. y discontinuesy discontinues ed to enter the d to enter the esignee prior esignee prio should be perfshould be re not availabnot availab ieeu of theu of the tubetub ning and Earlyning and E administered dministered ening and Basening and B ng hematologyg hematol .55, Procedure, Procedure de attempt is ide attempt is id ed as an adveed as an adv ed after subjeced after subje n the followinthe followin itch must be pmust be mpleted in thempleted in th$5<,1)250$7,21e Corporae Corpora 21 nsion Phasesion Phase7,2222 990$0$0$0$ 4 days)4 da2424 (Â±4Â±455025)222 --111)1,111 X<,5<XXXX5<5<5<$55<55I= The Derm= The De d fromd from subjectsubject7$5(7$"
33,page_33,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 33 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 20176. PROCEDURES The following administrative/demographic procedures will be conducted as outlined in the Table of Events, Table 3 . Informed Consent An informed consent form (ICF) must be signed by the subject before any study-related assessments are performed. Details of the informed consent process may be found in Section 13.3. Inclusion/Exclusion Criteria Subjects must meet all inclusion criteria (Section 4.2) and must not have any of the conditions specified in the exclusion criteria (Section 4.3) to qualify for participation in the study. The subjectâ€™s source documents must support his/her qualifications for the study (eg, if a female subject does not require pregnancy testing and birth control because of a hysterectomy, the date of the hysterectomy must be included in the medical history). Medical and Disease History Relevant medical history, as defined in the electronic Case Report Form (eCRF) Completion Guidelines and the Study Manual, should be r ecorded, including smoking and alcohol history, as well as previous relevant surgeries (please refer to the eCRF Completion Guidelines and the Study Manual for further details). Disease history includes history of psoriasis and psoriatic arthritis. Prior/Concomitant Medications and Therapies All medications and therapies being taken/used by the subject at the time of consent or at any time during the study should be recorde d. Other key medications and therapies, such as previous treatment for tuberculosis (TB) or relevant dis eases, should be recorded. Please refer to the eCRF Completion Guidelines and the Study Ma nual for additional instructions and for further details. All medications and therapies for psoriasis, including topicals (used within the last 5 years prior to randomization), systemics, and all medications and therapies for psoriatic arthritis, should be recorded. The stop dates for all medications and therapies prohibited in the study should be recorded. Responses to prior psoriasis therapies should also be recorded. Please refer to the eCRF Completion Guidelines and the St udy Manual for additional instructions. 6.1. Screening Period Screening evaluations will be performed for all subjects to determine study eligibility. These evaluations must be completed within 35 days of rando mization unless noted otherwise below. Waivers to the protocol will not be granted during the conduct of this trial, under any circumstances. Safety laboratory analyses and all assessments will be performed by the central laboratory. Screening laboratory values must demonstrate subject eligibility, but exclusionary results may be re-tested one time within the screening wi ndow, without Celgene Medical Monitor approval. CCI&(/*(1(35235,(7$5<,1)250$7,21condicondi titiiiono e study. Th study. Th (eg, if a fem(eg, if a fem hysterectomhysterectom port Form (port For uding smokding smok CRF CoRF Co mpml ludes histoludes histo pieses used bysed by ththyy d. Other kd. Other evant diseaevant di the Studythe Stud ies for psores for pso mics, and amics, and dates for allates for a ses to priores to prior oon Guidelin Guid ScreeniScreeni ening evaluening eval aluatuatioions mns m Waivers Waivers cum"
34,page_34,"EDMS Doc. Number: Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 34 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Subjects who fail initial screening may re-screen one additional t ime for the study. Efficacy assessments may be performed by the investigator or qualified designee at any time during the Screening Visit. However, wh en conducting the efficacy assessments, the investigator must complete these assessments in the following order: 1) ScPGA; The following assessments will be performed at screening as specified in the Table of Events, Table 3 , after informed consent has been obtained: !Demographics (initials, date of birth, sex, race, and ethnicity-if allowed by local regulations) !Prior disease therapies: includes topical, systemic, and phototherapies !Complete medical history (all relevant medical c onditions d iagnosed/ occurring prior to screening should also be included) !Height !Weight !Complete physical examination !Vital signs (including blood pressure, temperature, and heart rate) !Chest radiograph (historic scans within 12 weeks of screening are allowed) !12-lead electrocardiogram (ECG) !Scalp Physician Global Assessment !Hematology panel !Chemistry panel (including Hemoglobin A1C) !Urinalysis !Hepatitis B and C screening !TB testing !Serum pregnancy test is required for all female subjects of childbearing potential. Counseling about pregnancy precautions and the potential risks of fetal exposure !Adverse event assessment (begins when the subject signs the informed consent form) 6.2. Treatment Period The subject will begin treatment upon confirmation of eligibility. For visits within the Placebo- controlled Phase and Apremilast Extension Phase, an administrative window of Â± 4 days is CCICCI C CI &(/*(1(35anelel panel panel (i(incl ysisysis epatiepati titiiis B as B a TB testinTB test !SeruSer CC5235,(7$5<,1)250$7,21occurring occurring e, and heare, and hea eeks of screeks of sc 235 352"
35,page_35,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 35 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017permitted. For visits within the Observational Follow-up Phase, an administrative window of Â± 2 weeks from the last dose of IP is permitted. During the treatment period, subjects must complete the itch NRS and subject questionnaires prior to any other study procedure being performed. The subject should complete the questionnaires in the following order when a pplicable: 1) whole body itch NRS, 2) scalp itch NRS, 4) DLQI, During the treatment period, efficacy assessments may be performed by the investigator or qualified designee at any time during a study visit, but only after the subject has completed the NRS and health-related quality of life (HRQoL) assessments, when required. The investigator performing efficacy assessments shall make independent observations at a given study visit and shall not review previous assessments or subject-derived data in advance of conducting the assessments. When conducting the efficacy assessments, the investigator must complete these assessments in the following order: 1) ScPGA; . The following evaluations/assessments will be performed at the frequency specified in the Table of Events, Table 3 . !Patient reported outcomes or health-related quality of life (HRQoL) !Concomitant medications evaluation !Concomitant procedures evaluation !Vital signs !12-lead electrocardiogram (ECG) !Weight !!Hematology panel !Chemistry panel !Urinalysis !Adverse event evaluation (continuously) !Efficacy assessments (see Section 6.4) !Urine pregnancy test (prior to dosing on Day 1) !IP dispense and return !Photography (select site s and involving subjects signing a separate photography ICF) 6.2.1. End of Treatment An end of treatment (EOT) evaluation will be performed for subjects who are withdrawn from treatment for any reason as soon as possible af ter the decision to permanently discontinue treatment has been made. The end of treatment (Visit 10) assessments will also be performed for subjects who complete the study. CCICCI CCI CCI CCI &(/*(1(35235,(7$5<,1)250$7,21d the d the stigator stigator dydyvisivisiyy t andt andiii ctcting the ing the complete tcomplete . cy specifiey speci f lifefe(HRQRQ vent evaluaent eval cycyassessmassessm rine pregnarine pregna &IP IP ddispeisp !PhoPho 6.2.1.6.2 ne n)2 235"
36,page_36,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 36 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017During the end of treatment visit, subjects must complete the itch NRS and subject questionnaires prior to any other study procedure being performed. The subject must complete the questionnaires in the following order: 1) body itch NRS, 2) scalp itch NRS, 3) DLQI, . During the end of treatment visit, efficacy assessments may be performed by the investigator or qualified designee at any time during a study visit, but only after the subject has completed the NRS and HRQoL assessments, when required. The investigator performing efficacy assessments shall make independent observations at a given study visit and shall not review previous assessments or subject-derived data in advance of conducting the assessments. When conducting the efficacy assessments, the investigator must complete these assessments in the following order: 1) ScPGA, . The following evaluations will be performed as specified in the Table of Events, Table 3 : !Patient reported outcomes or health-related quality of life (HRQoL) !Concomitant medications evaluation !Concomitant procedures evaluation !Complete physical exam !Vital signs !Weight !Hematology panel !Chemistry panel !Urinalysis !Adverse event evaluation (continuously) !Efficacy assessments (see Section 6.4) !Serum pregnancy test !IP return !Photography (select sites and involving subjects signing a separate photography ICF) 6.3. Follow-up Period All subjects should be followed for 28 days after the last dose of IP for AE reporting, as well as SAEs made known to the Investigator at any time thereafter that are suspected of being related to IP, as described in Section 10.1. During the follow-up period, effi cacy assessments may be performed by the investigator or qualified designee at any time during a study visit. The investigator performing efficacy assessments shall make independent observation s at a given study visit and shall not review previous assessments in advance of conducting the assessments. When conducting the efficacy assessments, the investigator must complete these assessments in the following order: 1) ScPGA, CCIC CI CCI CCI&(/*(1(35235,(7$5<,1)250$7,21hen en n the the Tableable 33:: L)) continuouslntinuous see Section Section est est hyhy(select s(selecyy owow-up Peup P shoulshoul ddbe be ade known known described described uring the fouring the f qualified qualified ssessmssessm"
37,page_37,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 37 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017The following evaluations will be performed at the Observational Follow-up Visit as specified in the Table of Events, Table 3. !Concomitant medications evaluation !Concomitant procedures evaluation !Weight !Vital signs !Adverse event evaluation !Efficacy assessments (ScPGA, ) 6.4. Efficacy Assessments The following assessments will be conducted as outlined in the Table of Events, Table 3 : !Numeric Rating Scale Assessments Whole Body Itch Numeric Rating Scale Assessment Prior to any other procedures or a ssessments being performed during the treatment period, the subject w ill be asked to assess whole body itch and select a number on a scale of 0-10, where â€œ0â€ represents no itch, and â€œ10â€ represents the worst imaginable itch. The number selected by the subject will be recorded in the database. SeeAppendix C . The Whole Body Itch NRS scale has been validated among patients with moderate to severe plaque psoriasis, and a 4-point change from baseline was shown to be optimal for demonstrating a level of clinically meaningful improvement in itch severity (Kimball, 2016 ). Scalp Itch Numeric Rating Scale Assessment After completing the Whole Body Itch NRS, the subject will be asked to assess scalp itch and select a number on a scale of 0-10, where â€œ0â€ represents no itch, and â€œ10â€ represents the worst imaginable itch. The number selected by the subject will be recorded in the database. See Appendix D . The Scalp Itch NRS was derived from the Whole Body Itch NRS. !Scalp Physician Global Assessment The ScPGA is a measurement of overall scalp involvement by the Investigator at the time of evaluation. The ScPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. When making the assessment of overall scalp severity, the Investigator should factor in areas that have already been cleared (ie, have scores of 0) and not just evaluate remaining lesions for severity, ie, the severity of each sign is averaged across all areas of involvement, including cleared lesions. CCICCI CCI &(/*(1Scalp PhScalp Ph The The1(35235,(7$5<,1)250$7,21nts, ts, TableTable 33 rformoredddudu ody itch andody itch â€œ10â€ repre10â€ repr l be recordebe recor been validaeen valid int change int change icallycally mmyyeanean ting Scale Aing Scale WhoWho le Bole Bo umber on aumber on a worst imagiorst imag hhe database databa lp Itch NRlp Itch NR timti(1(*(1"
38,page_38,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 38 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017In the event of different severities across signs of psoriasis, the sign that is the predominant feature of psoriasis should be used to help determine the ScPGA score. See Appendix B for grading criteria. ! CCICCI &(/*(1(35235,(7$5<,1)250$7,21$ 250)21)2,1)<5<$5<$57$(7$5,(75,(35, 35235(31(3(1(*(1/*((/*(/*(/"
39,page_39,"EDMS Doc. Number: Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 39 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017 6.5. Safety Assessments !Contraception Education The risks to a fetus or to a nursing child from apremilast are not known at this time. Results of animal and in vitro studies can be found in the IB. All females of childbearing potential (FCBP) must use one of the approved contraceptive options as described in Section 4.2while on IP and for at least 28 days after administration of the last dose of the IP. The female subjectâ€™s chosen form of contraception must be effective by the time the female subject is randomized into the study (for example, hormonal contraception should be initiated at least 28 days before randomization). At screening and at baseline, and at any time during the study when a female subject of childbearing potentialâ€™s contraceptive measures or ability to become pregnant changes, the Investigator will educate the subject regarding contraception options and correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy. !Serum and Urine Pregnancy Tests for Females of Childbearing Potential (FCBP) A serum pregnancy test with a sensitivity of â‰¤ 25 mIU/mL will be required for FCBP subjects at screening and at the Early Termination or Last Treatment Visit. In addition, a local urine pregnancy test kit will be provided by the central laboratory and will be performed at the site on all FCBP subjects at the Baseline Visit, prior to dosing. An unscheduled pregnancy test s hould be performed if the FCBP subject has missed a menstrual period. !Chest Radiograph (CXR) A CXR is required during Screening. A PA v iew is required; an additional lateral view is strongly recommended but not required. Alternatively, PA or PA/lateral radiographs that were taken within the 12 weeks prior to screening will be accepted. Chest radiographs should be perfor med as indicated by local treatment guidelines or practice for monitoring while on immunosuppressive/immunomodulatory therapy. If such guidelines are not available/applicable, routine CXRs should be performed when clinically indicated. !Hepatitis B and C Hepatitis testing will include hepatitis B su rface antigen and anti-hepatitis C antibody. CCICCI &(/*(1(35235,(7$5<,1)250$7,21atat thi this times time e approved approved and for at lend for at l ubjectâ€™s chubjectâ€™s c ubject is ranubject is ra e initniiated aed during the suring the s easures or aeasures or a e subject ree subject r e contraceptcontracep y Tests for Tests for t with a senwith a sen g and at theand at the urine pregnurine pregn rformed at rformed at uunschedulnschedu menstrual menstrual st Radiogrst Radiogr A CXR A CXR is is view is sview is radidio ChCh"
40,page_40,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 40 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017!TB Testing The QuantiFERONÂ®-TB Gold test should be used in lieu of the tuberculin skin test (TST) or purified protein derivative (PPD) skin test if possible. This test result must be negative within one month prior to first administration of IP or prior completed treatment was documented. !Vital Signs, Height, and Weight Vital signs, including temperature, pulse, and seated blood pressure, will be taken during the visits indicated in Table 3. Height will be measured and recorded at Screening; weight will also be measured and recorded at screening and then as indicated in Table 3 . Body mass index (BMI) will be calculated at Screening. !Complete Physical Examination A complete physical examination includes evaluations of skin, nasal cavities, eyes, ears, lymph nodes, and respiratory, cardiovascular, gastrointestinal, neurological, and musculoskeletal systems. The complete physical examination is done at screening and at the Early Termination or Last Treatment Visit (Visit 10). !Vasculitis Assessment The PDE4 inhibitors, including apremilast, have been shown to produce inflammatory perivascular histopathological changes in animal studies (eg, rodent toxicology studies). The Investigator should be watchful for any signs and symptoms of vasculitis at all times. Any suspicion of vasculitis must be thoroughly investigated by taking pertinent patient history, doing a physical examination, reviewing adverse events, and performing diagnostic procedures, as clinically indicated. A subject with signs and symptoms of possible vasculitis should receive a thorough evaluation as described above, be managed as medically appropriate, and continued with follow-up until the signs and symptoms of vasculitis have resolved. !Psychiatric Evaluation Apremilast prescriber information (eg, Summary of Product Characteristics, Package insert) includes a warning regarding depression and suicidal thoughts. Patients with chronic diseases may be prone to depression. The risks and benefits of starting or continuing treatment with apremilast should be carefully assessed if patients report previous or existing psychiatric symptoms or if concomitant treatment with other medicinal products likely to cause psychiatric events is intended. At any time during the study (post-randomization), subjects who have suicidal thoughts or behavior should be evaluated. If the psychiatrist deems the subject not to be a risk for suicide, the subject may remain in the study, but if a risk of suicide is confirmed, the subject must be discontinued from the study. If the subject is discontinued, the subject should return for the Observational Follow-up Visit. A copy of the psychiatric evaluation report must be in the subjectâ€™s source documentation, especially if the subject is confirmed not to be at risk for suicide and is continuing in the study. CCI&(/*(1(35235,(7$5<,1)250$7,21ng.ng. al cavital cavit ies,ies nal, neurolnal, neurol nis done ais don it 10).t 10). been shownbeen show hanges in ahanges in a d be watchd be watch of vasculitof vasculi ing a physing a physi proceduresprocedures vasvasculiculititiiiss d as medicad as medi oms of vascms of v onon riber informriber inform s a warnings a warning eases mayeases may byy ng treatmeng treatmen ous or existous or exist edicinal prodicinal pr thhe studye study (p(yy shoulshoul d bd thhe sue mm"
41,page_41,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 41 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017!Twelve-lead Electrocardiogram A 12-lead ECG will be performed after the subject has been supine for approximately 3 minutes. ECGs will be performed at screening as indicated in Table 3. ECGs will be evaluated by a central reader. !Clinical Laboratory Evaluations Clinical laboratory evaluations will be performed by a central laboratory and as indicated in Table 3. Clinical laboratory evaluations include complete blood count (red blood cell [RBC] count, hemoglobin, hematocrit, white blood cell [WBC] count and differential, absolute WBC counts, platelet count); serum chemistries (total protein, albumin, calcium, phosphorous, glucose, total cholesterol [TC], triglycerides, high-density lipoprotein [HDL], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C ], adiponectin, uric acid, total bilirubin, alkaline phosphatase, aspartate aminotransferase [AST; serum glutamic-oxaloacetic transaminase, SGOT], alanine aminotransferase [ALT; serum glutamic pyruvic transaminase, SGPT], sodium, potassium, chloride, bicarbonate [carbon dioxide, CO 2], blood urea nitrogen, creatinine, lactate dehydrogenase [LDH], and magnesium); as well as Hemoglobin A1C at the Screening Visit, and dipstick urinalysis (specific gravity, pH, glucose, ketones, protein, blood, bilirubin, leukocyte esterase, nitrite, and urobilinogen). Dipstick urinalysis will be performed by the central laboratory; microscopic urinalysis (epithelial cells, RBC, WBC, and casts) will be performed only if the dipstick urinalysis is abnormal. Fasting is not required. However, if significant elevation of serum lipid(s) is observed, a fasting re-test should be requested to determine whether or not elevation was caused by eating. !Psoriasis Flare Assessments Psoriasis flare represents an atypi cal or unusual worsening of disease during treatment ( Carey, 2006 ). It is defined as a sudden intensification of psoriasis requiring medical intervention or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. A m ore typical, gradual worsening of plaque psoriasis would not be recorded as an adverse event (AE). !Adverse Events Details of AE reporting may be found in Section 10.1. CCICCI &(/*(1(35235,(7$5<,1)250$7,21oununt tnn al l glycerides,glycerides DLDL--C]C], l, lowow bilirubin, bilirubin, tamictam -oxaloxal glutamic pyutamic py nate [carbonnate [carb ase [LDH]se [LDH] ning Visit, ng Visit, rotein, bloootein, nalysis willalysis will ithelialhelial cell cellll alysis lysis is is abnabn gnificant elgnificant requested requested ss s an atyan aty picapicyyy 0606). It is de). It is d interventintervent ioio or pustulpustul ar par ululd not be rd not be EventsEvents ils oils of fAE rAE r /*((/(/*(/"
42,page_42,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 42 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017 6.7. Patient Reported Outcomes Questionnaires should be completed by the subject after the who le body itch NRS and scalp itch NRS efficacy assessments and in the order that they are described below and as indicated in Table 3 . ! !Dermatology Life Quality Index (DLQI) During the treatment phase (see Table 3 ), DLQI ( Finlay, 1994 ) will be assessed by the subject upon arrival at the site, after completing the Whole Body Itch NRS, S calp Itch NRS, and prior to any other procedures or assessments being performed. The DLQI was developed as a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease ( Finlay, 1994 ). The instrument contains 10 items dealing with the subjectâ€™s skin. With the exception of Item Number 7, the subject responds on a four-point scale, ranging from â€œVery Muchâ€ to â€œNot at All.â€ Item Number 7 is a multi-part item, the first part of which ascertains whether the subjectâ€™s skin prevented them from working or studying (Yes or No), and if â€œNo,â€ then the subject is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being â€œA lot,â€ â€œA little,â€ or â€œNot at all.â€ The DLQI Total score has a possible range from 0 to 30, with 30 corresponding to the worst health-related quality of life, and 0 corresponding to the best score. The developers suggest that the DLQI can be grouped into six subscales: symptoms and feelings; daily activities; leisure; work/school; personal relationships; and treatment. Scores for four of the subscales (symptoms and feelings, daily activities, leisure, and personal relationships) range from 0 to 6; scores for two of the subscales (work/school and treatment) range from 0 to 3. Higher scores correspond to poorer health-r elated qu ality of life. See Appendix F . CCICCI CCI CCI C CI&(/*(1(35235,(7$5<,1((Finlay, 199Finlay, 19 leteting the Wing the W rior torior to any oany oped as a sioped as a s y clinical sclinical s 19941994 ). Th). Th he exceptionexceptio g frog fro m mâ€œVâ€œVe art of whicart of w studying (Ystudying (Y blem the skiem the ski ives being ives bein otal score hotal score thth--relrelated ated pers suggesers sugges ings; dailyings; daily1)250$7,21NRS and RS and d below d below cores for focores for f personal personal (workwork heahea)21)2,1) &(C C"
43,page_43,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 43 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017 6.8. Photography Photographic assessments will be done at selected sites to provide supportive evidence of efficacy as scheduled in Table 3 . The procedure for taking the photographs and processing and shipping photographs will be described in a separate procedure manual distributed to investigational sites performing photographic assessments. Photographic assessments are an optional part of this study. Subjects enrolled at the selected photography sites will be asked to provide separate consent prior to being photographed. CCIC CI &(/*(1(35235,(7$5<,1)250$7,21parate parate ic enrolled aenrolled a nt prior to bnt prior to"
44,page_44,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 44 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 20177. DESCRIPTION OF STUDY TREATMENTS 7.1. Description of Investigational Product(s) The chemical name of apremilast (CC-10004) is acetamide, N-[2-[(1S)-1-(3-ethoxy-4- methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]. Apremilast will be supplied by the Sponsor, Celgene Corporation, and labeled appropriately as investigational product for this study. All IP will be provided in blister cards throughout the entire study. Apremilast will be provided as 10, 20, or 30 mg tablets. Placebo will be provided as ident ically appear ing 10, 20, or 30 mg tablets. Apremilast, the investigational product (IP), will be taken orally twice daily, approximately 12 hours apart, without restrict ion of food or drink. To mitigate potential gastrointestinal (GI) side effects, dose titration will be implemented in the first week of this study (see Table 4 ). During Week 0 (Days 1-7), subjects will be dispensed dose titration blister cards with 10, 20, and 30 mg apremilast tablets or identically appearing placebo tablets. The blister cards will contain all IP required for 4 weeks of treatment, with the first 7 days containing the titration supplies or matching placebo (see Table 4 Treatment Schema for Dose Titration at Visit 2 [Week 0] which details the titration supplies from Day 1 to Day 7). At Visit 2 (Week 0), subjects who meet entry criteria will be randomized using a permuted block randomization in parallel 2:1 to receive either apre milast 30 mg BID or placebo, using a centralized Interactive Response Technology (IRT). IP will be dispensed as indicated below. !Weeks 0 to 16: Double-blind, Placebo-controlled Treatment Phase: Apremilast 30 mg BID or placebo BID. âˆ€Week 0 to 1: subjects will be dose titrated as described above and detailed in Table 4 . !Weeks 16 to 32: Apremilast Extension Phase: Apremilast 30 mg BID. âˆ€Week 16 to 17: subjects will be dose titrated as described below and detailed inTable 5 . Starting at Week 16, all subjects will be switched to, or will continue with apremilast. Subjects originally randomized to placebo at Week 0 will be switched to apremilast 30 mg BID at Week 16. Dose titration blister cards will be used for subjects switching from placebo to apremilast; dummy titration blister cards (dosing at 30 mg BID directly) will be used for subjects initially randomized to receive apremilast 30 mg BID. At all other visits during the Apremilast Extension Phase, all subjects w ill receive apremilast 30 mg tablets which are to be taken twice daily. CCI&(/*(1(35235,(7$5<,1)250$7,21ided ded 30 mg 0 mg entientialal week of thisweek of this er cards witr cards blister cardblister car ning the titning the tion at Vin at Vi ss be randobe rando m ast 30 mg Bast 30 mg B IP will beIP will b boo-cocontnrollrol s will be dowill be d emilast Extemilast Ex to 17: subjto 17: su e5. all subjectsall subjec ized to placzed to plac titration btitration b dummy dummy tititratrii andomized domized ioonnPhase, hase, yy.."
45,page_45,"EDMS Doc. Number: Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 45 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017The treatment schema for dose titrati on at baseline is shown in Table 4. Table 4: Treatment Schema for Dose Titration at Visit 2 (Week 0) Week 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6-7 AM PM AM PM AM PM AM PM AM PM AM PM Apremilast 30 mg BID10mg A 20mg P 30mg P10mg P 20mg P 30mg P10mg A 20mg P 30mg P10mg A 20mg P 30mg P10mg A 20mg P 30mg P10mg P 20mg A 30mg P20mg A 30mg P20mg A 30mg P20mg A 30mg P20mg P 30mg A20mg P 30mg A20mg P 30mg A Placebo 10mg P 20mg P 30mg P10mg P 20mg P 30mg P10mg P 20mg P 30mg P10mg P 20mg P 30mg P10mg P 20mg P 30mg P10mg P 20mg P 30mg P20mg P 30mg P20mg P 30mg P20mg P 30mg P20mg P 30mg P20mg P 30mg P20mg P 30mg P A=Apremilast; BID= twice daily; P= Placebo. During Weeks 16 to 32, the IP will remain blinded, to prevent study personnel and subjects from knowing the IP assignment in th e Placebo-controlled Treatment Phase and to maintain the blind regarding the initial treatment assignment, all subjects will rece ive dose titration cards at Visit 7 (Week 16). Alt hough only subjects initially randomized to place bo will be dose titrated during their first week of the Apremilast Extension Phase, all subjects entering the Apremilast Extension Phase will receive identically-appearing titration/treatment cards as shown in Table 5 . CCIpriprietet,(7$5<,1)250$7,21e Corporae Corpora 21 $7 Day 5Day 50 MM P55525 A mg Pg P20mg A20mg 30m30m222 12 mg PP20mg P20mg 30m30m,111 $55<551 ersonnel anersonnel a rding the inrding the in allyallyrandomrandomyy g the the ApremAprem"
46,page_46,"EDMS Doc. Number: Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 46 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Table 5: Treatment Schema for Dose Titration at Visit 7 (Week 16) Week 16 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6-7 AM PM AM PM AM PM AM PM AM PM AM PM Apremilast 30 mg BID10mg P 20mg P 30mg A10mg P 20mg P 30mg A10mg P 20mg P 30mg A10mg P 20mg P 30mg A10mg P 20mg P 30mg A10mg P 20mg P 30mg A20mg P 30mg A20mg P 30mg A20mg P 30mg A20mg P 30mg A20mg P 30mg A20mg P 30mg A Placebo to APR 30 BID10mg A 20mg P 30mg P10mg P 20mg P 30mg P10mg A 20mg P 30mg P10mg A 20mg P 30mg P10mg A 20mg P 30mg P10mg P 20mg A 30mg P20mg A 30mg P20mg A 30mg P20mg A 30mg P20mg P 30mg A20mg P 30mg A20mg P 30mg A A=Apremilast; BID= twice daily; P= Placebo. CCI&(/*(1(35235,(7$5<,1)250$7,21e Corporae Corpora 21 priprietet7,2 50$$$$ PMPM05 20mg P 20mg P 30mg A30m555 125 20mg A0mg A 30mg P30m111) 5<5<5<5<1"
47,page_47,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 47 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 20177.2. Treatment Administration and Schedule Investigational product will be taken orally twice daily, approximately 12 hours apart, without restriction of food or drink. To mitigate potential gastrointestinal (GI) side effects, dose titration will be implemented in this study. During Week 1 (Days 1-7) and Week 16 (when placebo subjects are switched to receive apremilast 30 mg BID), subjects will be dispensed blister cards with 10, 20, and 30 mg apremilast tablets or identically appearing placebo for the dose titration. At all other visits where IP is dispensed, a premilast will be provided in blister cards as 10, 20, and 30 mg tablets or identically appearing placebo tablets. The treatment schema for dose titration at baseline and Week 16 is shown in Table 4 and Table 5. Blister card configurations are pictured in Appendix M , Appendix N , and Appendix O . 7.3. Overdose Overdose, as defined for this protocol, applies to protocol-required dosing of the investigational product(s) only. Therefore, for a drug to be subject to the overdose definition it must be both required and an investigational drug. In this study the only required and investigational drug is apremilast and the control arm drug (ie, placebo), he nce overdose definition will apply to only apremilast (or matching pl acebo). Other required or optional non-IP intended for prophylaxis of certain side effects, etc, are excluded from this definition. Overdose for this protocol, on a per dose basis, is defined as ingestion of 4 or more 30 mg apremilast (or matching placebo) tablets in any 24-hour period whether by accident or intentionally. On a schedule or frequency basis, an overdose is defined as dosing more than 4 times during any 24-hour peri od. 7.4. Method of Treatment Assignment At Visit 2 (Week 0), subjects who meet entry criteria will be randomized using a permuted block randomization in parallel 2:1 to receive either apr emilast 30 mg BID or placebo, using a centralized Interactive Response Technology (IRT). Designated research personnel at the investigational sites will be assigned passw ord protected, coded identification numbers, which gives them authorization to enter the IRT to randomize subjects. The system will present a menu of questions by which the research center personnel will identify the subject and confirm eligibility. When all questions have been answered and the subject deemed eligible, the IRT will assign a randomization identification number. Confirmation of the randomization will be sent to the investigational site, Celgene, and/or its representative. The confirmation reports should be maintained as source documents. During the study visits, the pharmacy or authorized study pers onnel at the investigational site will dispense coded IP kits in accordance with the rando mization number assigned by the IRT. 7.5. Packaging and Labeling The label(s) for IP may include, but may not be limited to, Sponsor name, address and telephone number, the protocol number, IP name, dosage form and strength (where applicable), amount of IP per container, lot number, expiry date (w here applicable), medication identification/kit number, dosing instructions, storage conditions, and required caution statements and/or CCI&(/*(1(35235,(7$5<,1)250$7,21ions ions the investthe invest igi ioon nitit mmustustmmm nd investid investi ga finitnitioion wilnw i IPPintendeende as ingestingest ioio periperiod whod wh verdose is dverdose i ignmentgnment entryentry cricriytetii ve eitve eit her apher TechnoTechn loogyg igned passwgned passw enter the IRenter the a menu oa menu o f rm eligibilim eligibi he IRT willhe IRT wil of f ththe rande ran ive. The cove. The co sits, the phthe phi d IP kid IP ki ts in ini &7.5.7.5. he lhl"
48,page_48,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 48 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017regulatory statements as applicable. Addition al information may be included on the label as applicable per local regulations. 7.6. Investigational Product Accountability and Disposal The Investigator(s) or designee(s) is responsible for accounting for all IP that is issued to and returned by the subject during the course of the study. The Investigator(s) or designee(s) is responsible for taking an inventory of each shipment of IP received, and comparing it with the accompanying IP accountability form. The Investigator(s) or Pharmacist(s) will verify the accuracy of the information on the form, sign and date it, retain a copy in the study file, and return a copy to Celgene. At the study site, all IP will be stored in a locked, safe area to prevent unauthorized access. The IP should be stored as directed on the package label.Celgene (or designee) will review with the Inve stigator and relevant site personnel the process for IP return, disposal, and/or destruction including responsibilities for the site versus Celgene (or designee). 7.6.1. Record of Administration Accurate recording of all IP administration (including dispensing and dosing) will be made in the appropriate section of the subjectâ€™s eCRF and source documents. 7.7. Investigational Product Compliance Study personnel will review the instructions printed on the package with the study subjects prior to dispensing the IP. Investigational product will be dispensed as noted in the Table of Events,Table 3. The subjects will be instructed to return the IP containers, including any unused medication, to the study site at each visit for tablet counts and reconciliation. Subjects will be asked whether they have taken their IP as inst ructed at each study visit. Any problems with IP compliance will be reviewed with the subject. If a subject misses 4 or more consecutive days of dosing, Celgene should be contacted to decide whether dosing should resume or whether the subject should be terminated from the Treatment Phase of the study, and enter into the Observational Follow-up Phase. Gross compliance problems (eg, missing 4 or more consecutive days of dosing or taking less than 75% of the doses between study visits) are prot ocol deviations and should be discussed with Celgene. Overall compliance with the study treatment regimen is defined as taking between 75% and 120% of the expected doses during a subjectâ€™s participation while in the treatment phases (Placebo-controlled Phase and Apremilast Extension Phases) of the study. CCI&(/*(1(35235,(7$5<,1)250$7,21s) or or in a in a access.access. rsonnel thersonnel the he sie site verste vii nsing and dnsing and d uments.uments. anceance inted on thnted on th t will be dit will be di to return tho return th sit ft fior tablor tablfff r IP as instrIP as inst hh the subje the subjehh ntacted to dntacted to ed from thed from th up Phase.p Phase. problems (problems ( doses betwdoses betw erall call comomplpm 20% of 0% of ththe (Pl(Pacebocebo --cc"
49,page_49,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 49 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 20178. CONCOMITANT MEDICATIONS AND PROCEDURES Over the course of this study, additional medications may be required to manage aspects of the disease state of the subjects, including side e ffects from trial treatments or disease progression. For information regarding other drugs that may interact with IP and affect its metabolism, pharmacokinetics (PK), or excretion, please see the Investigatorâ€™s Brochure and/or local package insert. 8.1. Permitted Concomitant Medications and Procedures Subjects may take any med ication that is not restricted by the protocol and would not be expected to interfere with the conduct of the study or affect assessments. Chronic medication should be dosed on a stable regimen. All medications (prescription and non-prescripti on), treatments and th erapies taken by the subject from screening throughout their entire participation in the study, including those initiated prior to the start of the study, must be recorded on the subjectâ€™s source document and on the appropriate page of the eCRF. The dose, unit, frequency, route, indication, the date the medication was started and the date the medication was stopped (if not ongoing) must be recorded. The recording of any permitted topical medications taken for psoriasis should also include the area of the body to which they are applied and the frequency of application. The following topical therapies will be permitted during the study: !For body lesions: unmedicated emollients !For scalp lesions: non-medicated shampoos 8.2. Prohibited Concomitant Medications and Procedures The following psoriasis medications cannot be administered for the duration of the study: !Topical therapy !Topical therapy, including, but not limited to, topical corticosteroids, retinoids or vitamin D analog preparations, tacrolimus, pimecrolimus, or anthralin/dithranol for body lesions; coal tar, salicylic acid preparations, or medicated shampoos for scalp lesions, or as specified in Section 8.1. !Intralesional corticosteroid injections for psoriasis lesions !Conventional systemic therapy !Systemic therapy including but not limited to cyclosporine, corticosteroids, methotrexate, retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, or fumaric acid esters !Phototherapy !UVB or PUVA CCI&(/*(1(35235,(7$5<,1)250$7,21dicaticatioon n aken by theken by th luding thosluding tho ocument ancumen atioion, the dan, the d not ongoinnot ongo ken for psoken for pso e frequencyfrequenc the studyhe study : mpoos mpoos MeMedicatiodicati nnot be adnot be ad y, includingy, includin nalog prepaalog prep lesiesons; cos; c esiesionons, or as, o esisiononalal cortcorll ConventionaConventiona !SySysts m !"
50,page_50,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 50 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017!Biologic agents, including: !TNF or IL-17 blockers, anti-IL-12 or anti-IL-23 monoclonal antibodies or biosimilars for each !Use of any investigational drug or device !Prolonged sun exposure or any use of tanni ng booths or other ultraviolet light sources 8.3. Required Concomitant Medication Not applicable. CCI&(/*(1(35235,(7$5<,1)250$7,21"
51,page_51,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 51 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 20179. STATISTICAL CONSIDERATIONS 9.1. Overview This is a Phase 3, multi-center, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp. Treatment assignment will be stratified by baseline ScPGA score [moderate (3), or severe (4)]. The objective of the statistical analysis will be to evaluate the efficacy and safety of apremilast 30 mg BID versus placebo for 16 weeks, and to evaluate the effects of apremilast 30 mg BID as a treatment for up to 32 weeks in subjects with moderate to severe plaque psoriasis of the scalp. After all subjects have completed the Placebo-controlled Phase (Weeks 0 to 16), the primary analysis will be performed. At the study comple tion, ie, when all subjects have also completed the Apremilast Extension Phase (Weeks 16 to 32) and the Observational Follow-up Phase, the final analysis will be performed. To maintain the blind at the site and subject level, the individual subject treatment assignments will not be revealed to the investigators until after the final database lock following the study completion. 9.2. Study Population Definitions The safety population will consist of all subjects who are randomized and received at least one dose of IP (IP). Subjects will be included in the treatment group corresponding to the IP they actually receive. The intent-to-treat (ITT) population will consist of all sub jects who are randomized. Subjects will be included in the treatment group to which they are randomized. The per protocol (PP) population will consist of all subjects included in the ITT population who receive at least one dose of IP (IP), have both baseline and at least one post-treatment ScPGA evaluation, and have no protocol deviations which may affect analyses in the Placebo-controlled Phase. 9.3. Sample Size and Power Considerations The sample size est imation is based on the results of the Phase 3 and 3b studies, including CC- 10004-PSOR-008, PSOR-009 and PSOR-010 which demonstrated positive treatment effectsbetween apremilast 30 mg BID and placebo in the proportion of subjects achieving ScPGA response at Week 16 (range 18% to 29%). Approximate ly 300 subjects will be randomized in a 2:1 ratio to apremilast 30 mg BID or placebo. With this sample size, a chi-square test at the 2-sided 0.05 significance level will have 90% pow er to detect a minimum treatment difference of 18% (38% for apremilast 30 mg BID versus 20% for placebo) between the two arms for proportions of subjects achieving ScPGA response at Week 16 (defined as ScPGA score of clear [0] or almost clear [1] with at least a 2 point reduction from baseline at Week 16). If at least 60% of the approximate 300 randomized subjects would be evaluable for the whole body itch NRS an alysis, the subset sample size of 180 subjects will provide 90% power to detect a treatment difference of 25% (45% for apremila st 30 mg BID and 20% for placebo) in the CCI&(/*(1(35235,(7$5<,1)250$7,21st BID asID as he scalp.he scalp. e primary e primary also comalso com plplm oow-w-up Phasup Pha ect level, thct level, th until after thuntil after andomizedndomize ent group cent group of f all all subjesubje ich theych they areareyy nsist of all snsist of all s vebothboth basas viatiiationons s whw and Pownd Pow ttioion n is basis bas PSORSOR --009 009 ast 30 mg Bast 30 mg B Week 16 (rek 16 (r aa apremilastapremilast 05 siignificagnific (38% for (38% for a oportioporti ons oons o [0]0]or almalm at ltl"
52,page_52,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 52 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017proportion of subjects with â‰¥4-point improvement from baseline in the whole body itch NRS score. 9.4. Background and Demographic Characteristics Subjectâ€™s age, height, weight, and baseline char acteristics will be summar ized using descriptive statistics, while sex, race and other categorical variables will be provided using frequency tabulations. Medical history data will be summarized using frequency tabulations by Medical Dictionary for Regulatory Activities (MedDRA) system organ class and preferred term. 9.5. Subject Disposition Subject disposition (analysis population allocat ion, entered, discontinued, along with primary reason for discontinuation) will be summarized using frequency tabulations and percent for the Placebo-controlled Phase (Weeks 0 to 16) and the Apremilast Extension Phase (Weeks 16 to 32). A summary of subjects enrolled by site will be provided. Protocol deviations will be summarized using frequency distributions. 9.6. Efficacy Analysis 9.6.1. Efficacy Evaluation for the Placebo-controlled Phase (Weeks 0 to 16) Statistical comparisons will be made between apremilast 30 mg BID and placebo. All statistical tests will be at the 2-sided 0.05 significance level and the corresponding p-values will be reported. Data summaries will be provided for the two randomized treatment arms (apremilast 30 mg BID and placebo). 9.6.1.1. Primary Efficacy Endpoint The primary endpoint is the proportions of subjects who achieving ScPGA response at Week 16 (defined as ScPGA score of clear [0] or almost cl ear [1] with at least a 2-point reduction from baseline at Week 16). It will be analyzed using the ITT population. A sensitivity analysis will be performed using the PP population. The treatment difference between apremilast 30 mg BID and placebo will be compared using CMH (Cochranâ€“Mantelâ€“Haenszel) test adjusting for the stratification factor at randomization. The 2-sided p-values from the CMH test, the adjusted treatment difference in proportion using the weighted average of the treatment differences across the strata with the CMH weights, along with the associated 2-sided 95% CIs using a nor mal approximation to the weighted average will be provided. Missing values at Week 16 will be imputed using the multiple imputation (MI) method (SAS Institute Inc. 2008) as the primary analysis, with sensitivity analysis using the last observation carried forward (LOCF) met hod and the non-responder imputation (NRI) method. The SAS procedure MI will be used to impute missing ScPGA scores at the scheduled assessments in the Placebo-controlled Phase (Week s 0-16) to create M=25 complete data sets. The missing data patterns will be checked by treatment and stratification factor at Baseline (Week 0), and Weeks 2, 4, 8, 12 and 16. If there are non-monotone missing patterns, two separate imputation procedures will be used to complete the imputation process. CCI&(/*(1(35235,(7$5<,1)250$7,21h primaryh primary ercent for trcent for (Weeks 16(Weeks s will be s will be sus Phase (WePhase (W 30 mg BID30 mg BID the correspthe corresp wo randomwo random s of subjectof subjec ]or almoor almo st analyzed usanalyzed u tioion. n. between aprween apr lâ€“â€“HaenszelHaensze frofrom m ththe Ce rage of the rage of the ated 2ated 2 -sisided d.Missing Missing (SAS InstitAS Insti vatvatioion carrin carr he SAS prohe SAS pro assessmessessme he hemm"
53,page_53,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 53 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017In the first step, the Markov Chain Monte Carlo (MCMC) method will be used to impute missing scores by treatm ent and stratif ication factor to create M=25 imputed data sets with monotone missing patterns. The minimum and the maximum values for imputation will be 0 and 4, which correspond to the lowest and the highest Sc PGA scores. The seed will be set to 804529, the imputed values will be rounded to integers and a single chain will be used to produce imputations. In the second step, the predictive mean matching method will be used to impute the remaining missing values for the 25 data sets with monotone missing patterns. The MONOTONE REGPMM statement will be used with seed 447159. The missing values at each visit will be imputed based on treatment, stratification factor, and ScPGA scores at baseline and previous visits. The number of closest observations to be used in the selection will be K=2. After the completion of imputation, the same CMH method will be used to analyze the 25 complete data sets and the SAS procedure MIANALYZE will be used to combine the results for the statist ical inferences. 9.6.1.2. Secondary Efficacy Endpoints For the binary endpoints defined as â‰¥4-point reduction (improvement) from the baseline visit in either the whole body pruritus NRS score or the scalp pruritus NRS score at post-baseline visits, the analyses will be based on subjects in th e ITT population with ba seline whole body pruritus NRS score â‰¥4 or baseline scalp pruritus NRS score â‰¥4, respectively. For the continuous secondary endpoint (ie, change from baseline in DLQI total score at Week 16), the analyses will be based on ITT population. Unadjusted 2-sided p-values and 2-sided 95% confidence intervals (CIs) will be reported. In order to evaluate the onset of effect of apremilast 30 mg BID compared to placebo for itch, the following secondary endpoints are specified (Section 2): !Proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the whole body itch NR S score at Week 16 !Proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the scalp itch NRS score at Week 16 !Proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the overall body itch NRS score at Week 12, Week 8, Week 4, and Week 2 !Proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the scalp itch NRS score at Week 12, Week 8, Week 4, and Week 2 Statistical analyses for the ten e ndpoints will be performed one by one downward from Week 16 to Week 2. Multip licity adjustment is sp ecified in Section 9.6.1.3 . The binary endpoints will be analyzed similarly as the primary endpoint. The treatment difference at each time point between apremilast 30 mg BID and placebo will be compared using CMH (Cochranâ€“Mantelâ€“Haenszel) test adjusting for the stratification factor at randomization. The 2-sided p-values from the CMH test, the adjusted treatment difference in proportion using the weighted average of the treatment differences across the strata with the CMH weights, along with the associated 2-sided 95% CIs using a nor mal approximation to the weighted average will CCI&(/*(1(35235,(7$5<,1)250$7,21e ous us e the the 25 25 ine the resune the re ent) from thent) from NRS score NRS s wiwiththiii b hhaselisel spectively.spectively. total scoretotal score alues and 2alues and emilastemilast 30 30 ed (ed (SectionSectio hhâ‰¥4â‰¥4--poinpotn core at Were at We ects wiects wi ththiiiâ‰¥4â‰¥ core at Wecore at W ofof subjects subjectsff odydyititchchNN portiportion ofon of suff calp calp ititchchNRNR al analyses nalyse ek 2. Multek 2. Mult he binary ehe binary differencedifferenc MH MH"
54,page_54,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 54 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017be provided. Missing values will be imputed using the similar MI method as the primary endpoint, with sensitivity analysis using the LOCF method and NRI method. The continuous endpoint (ie, change from bas eline in DLQI total score at Week 16) will be analyzed based on the ITT population using the analysis of covariance (ANCOVA) model. The ANCOVA model will use the change from baseline as the dependent variable and will include treatment group and stratification fact or as independent variables and the baseline value as a covariate variable. Within- group least-squa res (LS) mean changes from baseline at Week 16, the associated standard errors (SEs) and 2-sided 95% CIs, treatment differences in LS mean changes from baseline, and the associated 2-sided 95% CIs and p-values, will be derived from the ANCOVA model. Missing values at Week 16 will be imputed using the MI method, with sensitivity analysis using the LOCF method. 9.6.1.3. Multiplicity Adjustment The primary and secondary efficacy endpoints will be hierarchically ranked for testing in order to control the overall type I error rate in claiming statistical significance at the 2-sided 0.05 significance level. Specifically, for the primary efficacy endpoint (ScPGA response at Week 16), if the 2-sided p-value from the comparison between apremilast 30 mg BID and placebo is below 0.05, the outcome will be considered statistically significant and apremilast 30 mg BID will be declared effective. For any secondary endpoint, statistical significance will be claimed only if its 2-sided p-value is below 0.05 and tests for the primary endpoint and all previous secondary endpoints are significant at the 2-side d 0.05 level. The proposed test sequence for the primary and secondary efficacy endpoints is listed as the following: !Proportion of subjects with ScPGA score of cl ear (0) or almost clear (1) with at least a 2-point reduction from baseline at Week 16 !Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the whole body itch NR S score at Week 16 !Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the scalp itch NRS score at Week 16 !Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the whole body itch NR S score at Week 12 !Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the scalp itch NRS score at Week 12 !Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the whole body itch NR S score at Week 8 !Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the scalp itch NRS score at Week 8 !Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the whole body itch NRS score at Week 4 !Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the scalp itch NRS score at Week 4 CCI&(/*(1(35235,(7$5<,1)250$7,21es es h for testing for testing the 2the 2 -siided PGA responGA respo 30 mg BID0 mg BID nt and apreand apr ical significcal signi imary endpmary end evel. vel. The pThe the fothe fo llollow core of cleaore of clea t Week 16t Week 16 point redupoint redu at Week 1t Week 1 withthiâ‰¥4 poi poi at Week 1at Week 1 ubjects wibjects wi thtii chchNRS scRS n ofn of subje subjeff ttchchNRS sNRS s roportiroporti on oon o whowholelebobo !!PropoProp scsc !"
55,page_55,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 55 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017!Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the whole body itch NRS score at Week 2 !Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the scalp itch NRS score at Week 2 !Change from baseline in Dermatology Life Quality Index total score at Week 16 9.6.1.4. Exploratory Endpoints Descriptive summary statistics or proportion of subjects achieving specified criteria will be summarized by treatment group. When a ppropriate, exploratory endpoints at Week 16 will also be analyzed using CMH or ANCOVA methods similar to the primary and secondary endpoints. 9.6.1.5. Subgroup Analysis Subgroup analyses for ScPGA response at Week 16 and proportions of subjects with â‰¥4-point reduction (improvement) from baseline in the w hole body itch NRS or scalp itch NRS scores at post baseline time points based upon baseline dem ographic (age, gender, race, etc.) or baseline disease characteristics will be provided to determine the robustness of the treatment effect. 9.6.2. Efficacy Evaluation â€“ Apremilast Extension Phase (Weeks 16 to 32) Efficacy endpoints for time points beyond Week 16 will be summarized according to the treatment assigned at randomization. For all subj ects, changes in measurements will be calculated relative to measurements obtained at baseline (Week 0). Descriptive summary statistics or proportion of subjects achieving specified criteria will be summarized by treatment group. For continuous variables, descriptive statis tics for baseline and changes or percent changes from baseline will be provided. Categorical variables will be summarized with frequency tabulations. 2-sided 95% confidence in tervals will be provided for changes or percent changes and response rates. 9.7. Safety Analysis The safety analyses will be performed using the safety population as defined in Section 9.2. Safety will be assessed by clinical review of all relevant parameters including treatment-emergent adverse events (TEAEs), laboratory tests, vital signs, and ECG measurements; no inferential testing for statist ical signif icance will be performed. Adverse events will be classified using the Medical Dictionary for Regulatory Activities (MedDRA) classification system. Adverse events will be tabulated for the Placebo-controlled Phase (Weeks 0 to 16) and the Apremilast Expos ure Phase in the study. All TEAEs will be summarized by system organ class, preferred term, severity, and relationship to IP. Adverse CCICCI &(/*(1(35235,(7$5<,1)250$7,21l also l also ndpondpo intints.s. cts wicts w thhiâ‰¥4â‰¥4 lp p lititchchNRNR er, race, etcr, race, e of the treatmf the treat milast Extemilast Exte yoyond Weeknd W n.For all sFor all s ents obtainents obtain bjects achiebjects achie riables, desciables, des will be prowill be pro ns.2-2-sidedsided onse rates.onse rates. Safety AnSafety An fetety yanalysenalys tty y will be awill be eatmeatm entent--eme measuremmeasurem$5<7$57$(7$5,(7"
56,page_56,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 56 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017events leading to death or to IP withdrawal and serious AEs will also be summarized and listed separately. Data from other safety assessments will be summarized descriptively. Shift tables for laboratory parameters showing the number of subjects with values low, normal, and high compared with the normal reference ra nges pre-treatment versus post-treatment will be provided. To account for the different exposure to the investigational product, adverse events or marked laboratory a bnormalities will also be summarized using the exposure adjusted incidence rate, in addition to the simple incidence rates. By-subject listings will be provided for all relevant safety data. 9.8. Interim Analysis No interim analysis will be conducted. After all subjects have completed the Week 16 Visit (or discontinued from the study), a Week 16 database lock will be performed, the primary data analysis will be conducted . However, unblinded data will only be made available to select Sponsor and Contract Research Organization (CRO) team members involved with analysis of the data All other Sponsor, site, and CRO personnel directly involved with the conduct of the study, will remain blinded to treatment assignments until the final database lock at the conclusion of the study. At the end of the study, after all sub jects have completed, or have been discontinued from the Apremilast Extension Phase (Weeks 16 to 32) and the Observational Follow-up Phase, the final analysis will be performed and a final Clinical Study Report will be generated. 9.9. Other Topics 9.9.1. Investigational Product Compliance (Tablets) Investigational product record information will be summarized. Overall compliance will be estimated by the proportion of subjects who take between 75% and 120% of the intended quantity of IP. 9.9.2. Concomitant Therapy All concomitant treatments documented during the study period will be summarized in frequency tabulations. The Anatomical Therapeutic Chemical (ATC) coding scheme of the World Health Organization (WHO) will be used to group me dications into releva nt categories for these tabulations. 9.9.3. Steering Committee Guidance in protocol development and inter pretation of data analysis will be provided by a scientific steering committee (SSC). Det ails for the SSC are pre-s pecified in a separate SSC charter. CCICCI CCI CCI &(/*(1(35235,(7$5<of the studyof the stud onclusionclusio n n en disconten discont ii ional Foional Fo lloll wilill l be generbe gene CompliancComplianc ormatormat ion wn subjects whubjects w ant Therapnt Therap eatmeatm ents dents d e Anatomice Anatomic n (WHO) wn (WHO) w s. .. SteeSte GuiGuidance idance i scientificientif art<,1)250$7,21the studythe study ),),yy cted ted ll only be mll only be m m members imembers1)2CCI 5<,"
57,page_57,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 57 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 20179.9.4. Internal Celgene Safety Monitoring During the Apremilast Program: Role of the Safety Management Team In addition to daily safety monitoring conducted by investigators and individual study personnel, cumulative and interval blinded adverse events (AEs), serious adverse events (SAEs), discontinuations, and laboratory findings are reviewed internally by a Safety Management Team (SMT) at Celgene. The review follows the Council for International Organizations for Medical Sciences, Working Group VI (CIOMS VI) recommendations. The SMT is comprised of lead representatives from multiple Celgene functions engaged in the apremilast development program. The scope, conduct, processes, and accountabilities of the SMT are specified in theSMT charter. CCI&(/*(1(35235,(7$5<,1)250$7,21e"
58,page_58,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 58 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 201710. ADVERSE EVENTS 10.1. Monitoring, Recording and Reporting of Adverse Events An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomi tant impairment of the subjectâ€™s health, including laboratory test values (as specifi ed by the criteria in Section 10.3), regardless of etiology. Any worsening (ie, any clinically significant adverse ch ange in the frequency or intensity of a pre- existing condition) should be cons idered an AE. A diagnosis or syndrome should be recorded on the AE page of the case report form (CRF) rather than the individual signs or symptoms of the diagnosis or syndrome. Abuse, withdrawal, sensitivity or toxicity to an investigational product should be reported as an AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be reported on the overdose CRF. (See Section 7.3for the definition of overdose.) Any sequela of an accidental or intentional overdose of an investigational product should be reported as an AE on the AE CRF. If the sequela of an overdose is an SAE, then the sequela must be reported on an SAE report form and on the AE CRF. The overdose resulting in the SAE should be identified as the cause of the event on the SAE report form and CRF but should not be reported as an SAE itself. In the event of overdose, the subject should be monitored as appropriate and should receive supportive measures as necessary. There is no known specific antidote for apremilast overdose. Actual treatment should depend on the severity of the clinical situation and the judgment and experience of the treating physician. All subjects will be monitored for AEs during the study. Assessments may include monitoring of any or all of the following parameters: the subjectâ€™s clinical symptoms, laboratory, pathological, radiological or surgical findings , physical examination findings, or findings from other tests and/or procedures. All AEs will be recorded by the Investigator from the time the subject signs informed consent until 28 days after the last dose of IP as well as those SAEs made known to the Investigator at any time thereafter that are suspected of being related to IP. AEs and SAEs will be recorded on the AE page of the CRF and in the subjectâ€™s source documents. All SAEs must be reported to Celgene Drug Safety within 24 hours of the Investigatorâ€™s knowledge of the event by facsimile, or other appropriate method, using the SAE Report Form, or approved equivalent form. 10.2. Evaluation of Adverse Events A qualified Investigator will evaluate all adverse events as to: 10.2.1. Seriousness An SAE is any AE occurring at any dose that: !Results in death; !Is life-threatening (ie, in the opinion of the Investigator, the subject is at immediate risk of death from the AE); CCIed on d on of f ththe e reported aseported as n AE shoulAE shou ose.)ose.) Any sAny dbe reportebe rep quela must buela must n the SAE sthe SAE hould not bhould not b d as appropas appr specific anspecific an hhe clinical e clinical ng the studyng the study ththe subjece subjec findings, phfindings, ph e InvestiInvesti gatgat ose of IPose of IP as re suspectere suspe RF and in thF and in th y ywiwiththiiin 24in 2 iate methodiate metho EvaluatiEvaluati ified Invesified Inves 0.2.1.0.2.1. S An SAEAn SA"
59,page_59,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 59 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017!Requires inpatient hospitalization or prolongation of ex isting hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay); !Results in persistent or significant disability/incapacity (a substantial disruption of the subjectâ€™s ability to conduct normal life functions); !Is a congenital anomaly/birth defect; !Constitutes an important medical event. Important medical events are defined as those occurrences that may not be immediately life- threatening or result in death, hospitalization, or disability, but may jeopardize the subject or require medical or surgical intervention to prevent one of the other outcomes listed above. Medical and scientific judgment should be exercised in deciding whether such an AE should be considered serious. Events not considered to be SAEs are hospitalizations for: !a standard procedure for protocol therapy administration. However, hospitalization or prolonge d hospitalization for a complication of therapy administration will be reported as an SAE. !routine treatment or monitoring of the stud ied indication not associated with any deterioration in condition. !the administration of blood or platelet transfusion as routine treatment of studied indication. However, hospitalization or prolonged hospitalization for a complication of such transfusion remains a reportable SAE. !a procedure for protocol/disease-related investig ations (eg, surgery, scans, endoscopy, sampling for laboratory tests, bone marrow sampling). However, hospitalization or prolonge d hospitalization for a complication of such procedures remains a reportable SAE. !hospitalization or prolongation of hospitalization for technical, practical, or social reasons, in absence of an AE. !a procedure that is planned (ie, planned prior to start of treatment on study); must be documented in the source document and the CRF. Hospitalization or prolonged hospitalization for a complication remains a reportable SAE. !an elective treatment of or an elective pro cedure for a pre-existing condition, unrelated to the studied indication, that has not worsened from baseline. !emergency outpatient treatment or observation that does not result in admission, unless fulfilling other seriousness criteria above. If an AE is considered serious, both the AE page/screen of the CRF and the SAE Report Form must be completed. For each SAE, the Investigator will provide information on severity, start and stop dates, relationship to the IP, action taken regarding the IP, and outcome. CCI&(/*(1(35235,(7$5<,1)250$7,21or ve. ve. E should beE should be wever, hospwever, hos ministratiinistrati ono ation not astion n usioion nas rouas ro rolonged horolonged e SAE.e SAE. llated invesated inves one mne m arrowarrow a coma com plicplmmm ongationgati on oon e of an AE.e of an AE at is planneat is pla d in the soud in the sou zatiation fon for or fff ectective treaive trea nrelated to nrelated to eemergemerge unlesunl f an AE if an AE i scs must be cmust be c"
60,page_60,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 60 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 201710.2.2. Severity/Intensity For both AEs and SAEs, the Investigator must assess the severity/ intensity of the event based on the descriptions listed below. Mild !Asymptomatic or mild symptoms; clinical or diagnostic observations only !Intervention not indicated !Activities of daily life (ADLs) minimally or not affected !No or minimal intervention/therapy may be required Moderate !Symptom(s) cause moderate discomfort !Local or noninvasive intervention indicated !More than minimal interference with ADLs but able to carry out daily social and functional activities. !Drug therapy may be required Severe (could be non-serious or serious) !Symptoms causing severe discomfort/pain !Symptoms requiring medical/surgical attention/intervention !Interference with ADLs including inability to perform daily social and functional activities (eg, absenteeism and/or bed rest) !Drug therapy is required The term â€œsevereâ€ is often used to describe th e intensity of a specific event (as in mild, moderate or severe myocardial infarction); the event itself, however, may be of relatively minor medical significance (such as severe headache). This criterion is notthe same as â€œseriousâ€ which is based on subject/event outcome or action criteria associated with events that pose a threat to a subjectâ€™s life or functioning. Seriousness, not severity, serves as a gui de for defining regulatory obligations. 10.2.3. Causality The Investigator must determine the relationship between the administration of the IP and the occurrence of an AE/SAE as Not Suspected or Suspected as defined below: Not suspected: a causal relationship of the adverse event to IP administration is unlikely or remote , or other medications, therapeutic interventions, or underlying c onditions provide a sufficient explanation for the observed event. Suspected: there is a reasonable possibility that the administration of IP caused the adverse event. â€˜Reasonable possibilityâ€™ means there CCI&(/*(1(35235,(7$5<,1)250$7,21y out daily y out daily ttention/intttention/in nability to pability to p r bed rest)r bed rest) describe thescribe th ; the event ; the event headache). eadache). come ome or oacac ning. ning. veritrity,y, serv serv ausalityusality tigator musgator mus ence of an Ance of an A Not Not"
61,page_61,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 61 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017is evidence to suggest a causal relationship between the IP and the adverse event. Causality s hould be a ssessed and provided for every AE/SAE based on currently available information. Causality is to be reassessed and provided as additional information becomes available. If an event is assessed as suspected of being related to a comparator, ancillary or additional IP that has not been manufactured or provided by Celgene, please provide the name of the manufacturer when reporting the event. 10.2.4. Duration For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the event. 10.2.5. Action Taken The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable (eg, discontinuation, interruption, or dose reduction of IP, as appropriate) and report if concomitant and/or additional treatments were given for the event. 10.2.6. Outcome The Investigator will report the outcome of the event for both AEs and SAEs.All SAEs that have not resolved upon discontinuation of the subjectâ€™s participation in the study must be followed until recovered (returned to baseline), recovered with sequelae, or death (due to the SAE). 10.3. Abnormal Laboratory Values An abnormal laboratory value is considered to be an AE if the abnormality: !results in discontinuation from the study; !requires treatment, modification/ interruption of IP dose, or any other therapeutic intervention; or !is judged to be of significant clinical importance, eg, one that indicates a new disease process and/or organ toxicity, or is an exacerbation or worsening of an existing condition. Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion need to be documented as a serious adverse event. If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis or syndrome should be recorded on the AE page/screen of the CRF. If the abnormality was not a part of a diagnosis or syndrome, then the labor atory abnormality should be r ecorded as the AE. If possible, the laboratory abnormality should be r ecorded as a medical term and not simply as an abnormal laboratory result (eg, record throm bocytopenia rather than decreased platelets). CCI&(/*(1(35235,(7$5<,1)250$7,21dates of thdates of th AE or SAE, E or SAE priate) and priate) an nt. or both AEor both AE oon of the sn of the s aseline), recaseline), r ValuesValues nsidered tosidered t uatatioion n fromfrom ent, mnt, m odifiodifi ; or; or d to be of sd to be of s ess and/or oess and/or ndidititiiiion.on. ss of severiof sever o be documo be docum a laboratora laborator or syndromor syndrom art of art of"
62,page_62,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 62 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 201710.4. Pregnancy All pregnancies or suspected pregnancies occurring in a female subject of childbearing potential are immediately reportable events . Pregnancies and suspected pregnancies (including elevated Î²-subunit of human chorionic gonadotropin [ Î²-hCG] or positive pregnancy test in a female subject of childbearing potential regardless of disease state) occurring while the sub ject is on IP, or within 28 days of the subjectâ€™s last dose of IP, are considered immediately reportable events. Investigational product is to be discontinued immediately and the subject instructed to return any unused portion of the IP to the investigator. The pregnancy, suspected pregnancy, or positive pregnancy test must be reported to Celgene Drug Safety immediately by email, phone or facsimile, or other appropriate method, using the Pregnancy Initial Report Form, or approved equivalent form. The female subject may be referred to an obstetrician-gynecologist or another appropriate healthcare professional for further evaluation. The Investigator will follow the female subject until completion of the pregnancy, and must notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or abnormal outcome) using the Pregnancy Follow -up Report Form, or approved equivalent form. If the outcome of the pregnancy was abnormal (eg, spontaneous abortion), the Investigator should report the abnormal outcome as an AE. If the abnormal outcome meets any of the serious criteria, it must be reported as an SAE to Celgene Drug Safety by facsimile, or other appropriate method, within 24 hours of the Investigatorâ€™s knowledge of the event using the SAE Report Form, or approved equivalent form. All neonatal deaths that occur within 28 days of birth should be reported, without regard to causality, as SAEs. In addition, any infant deat h after 28 days that the Investigator suspects is related to the in utero exposure to the IP should also be reported to Celgene Drug Safety by facsimile, or other appropriate method, within 24 hours of the Investigatorâ€™s knowledge of the event using the SAE Report Form, or approved equivalent form. 10.5. Reporting of Serious Adverse Events Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in addition to being recorded on the AE page/screen of the CRF. All SAEs must be reported to Celgene Drug Safety within 24 hours of the Investigatorâ€™s knowledge of the event by facsimile, or other appropriate method (eg, via email), using the SAE Report Form, or approved equivalent form. This instruction pertains to initial SA E reports as well as any follow-up reports. The Investigator is required to ensure that the data on these forms is accurate and consistent. This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study (from the time the subject signs i nformed consent until 28 days after the last dose of IP) or any SAE made known to the Investigator at any time thereafter that are suspected of being related to IP. Serious adverse events occurring prior to treatment (after signing the ICF) will be captured. The SAE report should provide a detailed description of the SAE and include a concise summary of hospital records and other relevant documents. If a subject died and an autopsy has been performed, copies of the autopsy report and deat h certificate are to be sent to Celgene Drug CCI&(/*(1(35235,(7$5<,1)250$7,21the the orted to orted to ethodethod , , ppropriate ppropriate egnancyegnanc , any gnancygnancy (ei(eiyyti r approvedr approve s abortion)abort mal outcommal outcom afetafety yby faby fa ge oge of f ththe eee f birth shoubirth sho death after 2eath after 2 should also hould also , within 24 within 24 or approvedr approve erious Aderious A riterion for riterion ded on the ded on the y wiwiththiiin 24in 24 ate methodate method struction peruction p tigator is regator is r quirement quirement m m ththe time e time AE mAE m ade kade IP. SeriP. Seri"
63,page_63,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 63 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Safety as soon as these become available. Any fo llow-up data should be detailed in a subsequent SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety. Where required by local legislation, the Investigator is responsible for informing the Institutional Review Board/Ethics Committee (IRB/EC) of the SAE and providing them with all relevant initial and follow-up information about the event. The Investigator must keep copies of all SAE information on file including correspondence with Celgene and the IRB/EC. 10.5.1. Safety Queries Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via facsimile or electronic mail. The response time is expected to be no more than five (5) business days. Urgent queries (eg, missing causality assessment) may be handled by phone. 10.6. Expedited Reporting of Adverse Events For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of events suspected of being related to a premilast based on the Investigator Brochure. In the United States, all suspected unexpected serious adverse reactions (SUSARs) will be reported in an expedited manner in accordance with 21 CFR 312.32. Celgene or its authorized represe ntative shall notify the Investigator of the following information !Any AE suspected of being related to the use of IP in this study or in other studies that is both serious and unexpected (eg, SUSAR); !Any finding from tests in laboratory animals that suggests a significant risk for human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity. Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of these new serious and unexpected AE(s) or significant risks to subjects. The Investigator must keep copies of all pe rtinent safety information on file including correspondence with Celgene and the IRB/EC. (See Section 14.3 for record retention information). Celgene Drug Safety Contact Information: For Celgene Drug Safety contact information, please refer to the Serious Adverse Event Report Form Completion Guidelines or to the Pr egnancy Report Form Completion Guidelines. CCI&(/*(1(35235,(7$5<,1)250$7,21business siness e the expece the expe Brochure.Brochu ons (SUns (SU SASA 32.2. ttigator of tigator of of IP in thiof IP in USAR);USAR); nimals that nimals tha f mutagenicmutageni vestvestigator sigator ) or signifior signi of all pertf all pert ini d the IRB/Ed the IRB/ ontact Infontact I fetfety y contacconta GuidelinesGuidelines"
64,page_64,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 64 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 201711. DISCONTINUATIONS 11.1. Treatment Discontinuation The following events are considered sufficient reasons for discontinuing a subject from the investigational product(s): !Adverse event !Lack of efficacy !Withdrawal by subject !Death !Lost to follow-up !Non-compliance with IP !Protocol deviation !Pregnancy !Physician decision !Study terminated by Sponsor !Other (to be specified on the CRF) The reason for discontinuation of treatment should be recorded in the CRF and in the source documents. When a subject is discontinued from treatment, the Investigator should make every attempt possible to have the subject evaluated at the Ear ly Termination Visit within 4 days of the last intake of IP. The decision to discontinue a subject from treatment remains the responsibility of the treating physician, which will not be delayed or refused by the Sponsor. However, prior to discontinuing a subject, the Investigator may contact the Medical Monitor and forward appropriate supporting documents for review and discussion. 11.2. Study Discontinuation The following events are considered sufficient reasons for discontinuing a subject from the study: !Screen failure !Adverse event !Withdrawal by subject !Death !Lost to follow-up !Protocol deviation CCIbe recordedbe recorde nt, the Invent, the Inve he Early Tehe Early T ect frofm m tre ayed or refayed or ref ay contact tay contact t diiscussiscus on Discontiniscontin events are cvents are c Screen fScreen !AdAd !!"
65,page_65,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 65 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017!Pregnancy !Physician decision !Study terminated by Sponsor !Other (to be specified on the CRF) The reason for study discontinua tion should be r ecorded in the CRF and in the source documents. CCI&(/*(1(35235,(7$5<,1)250$7,21"
66,page_66,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 66 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 201712. EMERGENCY PROCEDURES 12.1. Emergency Contact In emergency situations, the Investigator should contact the responsible Clinical Research Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency Contact Information page of the protocol (after title page). In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be reached, please contact the global Emergency Call Center by telephone at the number listed on the Emergency Contact Information page of the protocol (after title page). This global Emergency Call Center is available 24 hours a day and 7 days a week. The representatives are responsible for obtaining your call-back information and contacting the on-call Celgene/contract research organization Medical M onitor, who will then contact you promptly. Note: The back-up 24-hour global emergency contact call center should only be used if you are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for emergency calls. 12.2. Emergency Identification of Investigational Products The blind must not be broken during the course of the study unless in the opinion of the Investigator, it is absolutely necessary to safely treat the subject. If it is medically imperative to know what IP the subject is receiving, IP should be temporarily discontinued if, in the opinion of the Investigator, continuing IP can negatively affect the outcome of the subjectâ€™s treatment. The decision to break the blind in emergency situations remains the responsibility of the treating physician, which will not be delayed or refused by the Sponsor. However, the Investigator may contact the Medical Monitor prior to breaking the blind to discuss unblinding, mainly in the interest of the subject. The Investigator should ensure that the code is broken only in accordance with the protocol. The Investigator should promptly notify the Medical Monitor of the emergency unblinding and the reason for breaking the blind, which should be clearly documented by the Investigator in the subjectâ€™s source documentation. Emergency unblinding should only be performed by the Investigator through the IRT by using an emergency unblinding personal identification number (PIN), and the Investigator should contact IRT for unblinded dose information. CCI&(/*(1(35235,(7$5<,1)250$7,21be e on ves are ves are ene/ene/contracontra bbe used if ye used if r designee fdesignee f ProductsProduct nlessnless in thin t ubject. If itject. If i porarily disporarily d the outcomthe outco uations remuations rem ed by the Sed by the S ing the blinng the bli the code ishe code i tify the Meify the Me which shouwhich sho ation.ion. g shoulshou d onon ng personag persona d dose infod dose info"
67,page_67,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 67 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 201713. REGULATORY CONSIDERATIONS 13.1. Good Clinical Practice The procedures set out in this study protocol pertaining to the conduct, evaluation, and documentation of this study are designed to ens ure that Celgene, its authorized representative, and Investigator abide by Good Clinical Practice (GCP), as described in International Council for Harmonisation (ICH) Guideline E6 and in accordance with the general ethical principles outlined in the Declaration of Helsinki. The study will receive approval from an IRB/EC prior to commencement. The Investigator will conduct all aspects of this study in accordance with applicable national, state, and local laws of the pertinent regulatory authorities. 13.2. Investigator Responsibilities Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in the local regulations. Celgene staff or an authorized representative will evaluate and approve all Investigators who in turn will select their staff. The Investigator should ensure that all persons assi sting with the study are adequately informed about the protocol, amendments, study treatments, as well as study-related duties and functions, including obligations of confidentiality of Celgene information. The Investigator should maintain a list of Sub-investigators and other appropriately qualified persons to whom he or she has delegated significant study-related duties. The Investigator is responsible for keeping a record of all subjects who sign an informed consent form (ICF) and are screened for entry into the study . Subjects who fail screening must have the reason(s) recorded in the subjectâ€™s source documents. The Investigator, or a designated member of the Investigatorâ€™s staff, must be available during monitoring visits to review data, resolve queries and allow direct access to subject records (eg, medical records, office charts, hospital charts, and study-related charts) for source data verification. The Investigator must ensure timely and accurate completion of CRFs and queries. The information contained in the protocol and amendments (with the exception of the information provided by Celgene on public registry websites) is considered Celgene confidential information. Only information that is previously disclosed by Celgene on a public registry website may be freely disclosed by the Investigator or its institution, or as outlined in the Clinical Trial Agreement. Celgene protocol, amendment a nd IB information is not to be made publicly available (for example on the Investigatorâ€™s or their institutionâ€™s website) without express written approval from Celgene. Information propos ed for posting on the Investigatorâ€™s or their institutionâ€™s website must be submitted to Celgene for review and approval, providing at least 5 business days for review. At the time results of this study are made available to the public, Celgene will provide Investigators with a summary of the results that is written for the lay person. The Investigator is responsible for sharing these results with the subject and/or their caregiver as agreed by the subject. CCI&(/*(1(35235,(7$5<,1)250$7,21Practice anPractice luate and aluate and a dyy are adeqare adeqyy y--related drelated d . The InvesThe I persons to persons to of all subjeof all sub dydy. Subjec. Subje ments.ments. of the Invesf the Inve e queries anqueries alal charts, achartsll st ensure timst ensure the protocothe protoc elgene on pgene on mmataion than th y disclosedy disclose CelCelgene prgene pr xample on xample o mmCelCelmm genegene nâ€™s websitewebsite ss days forss days for the time rethe time r Investnvest igatigat esponsespon"
68,page_68,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 68 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 201713.3. Subject Information and Informed Consent The Investigator must obtain informed consent of a subject and/or a subjectâ€™s legal representative prior to any study related procedures. Documentation that informed consent occurred prior to the study subjectâ€™s entry into the study and of the informed consent process should be recorded in the study subjectâ€™s source documents including the date. The original ICF signed and dated by the study subject and by the person consenting the study subject prior to the study sub jectâ€™s entry into the study, must be maintained in the Investigatorâ€™s study files and a copy given to the study subject. In addition, if a protocol is amended and it impacts on the content of the informed consent, the ICF must be revised. Study subjects participating in the study when the amended protocol is implemented must be re- consented with the revised version of the ICF. The revised ICF signed and dated by the study subject and by the person consenting the study s ubject must be maintained in the Investigatorâ€™s study files and a copy given to the study subject. 13.4. Confidentiality Celgene affirms the subject's right to protection against invasion of privacy and to be in compliance with ICH and other local regulations (w hichever is most stringent). Celgene requires the Investigator to permit Celgene's representatives and, when necessary, representatives from regulatory authorities, to review and/or copy any medical records relevant to the study in accordance with local laws. Should direct access to medical records require a waiver or authorization separate from the subjectâ€™s signed ICF, it is the responsibility of the Investigator to obtain such permission in writing from the appropriate i ndividual. 13.5. Protocol Amendments Any amendment to this protocol must be approved by the Celgene Clinical Research Physician/Medical Monitor. Amendments will be submitted to the IRB/EC for written approval. Written approval must be obtained before implementation of the amended version occurs. The written signed approval from the IRB/EC should specifically reference the Investigator name, protocol number, study title and amendment number(s) that is applicable. Amendments that are administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC for information purposes. 13.6. Institutional Review Board/Independent Ethics Committee Review and Approval Before the start of the study, the study protoc ol, ICF, and any other appropriate documents will be submitted to the IRB/EC with a cover letter or a form listing the documents submitted, their dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is sought. If applicable, the documents will also be submitted to the authorities in accordance with local legal requirements. IP can only be supplied to an Investigator by Celgene or its authorized representative after documentation on all ethical a nd legal requirements for starting the study has been received by CCI&(/*(1(35235,(7$5<,1)250$7,21ol is ol is Study Study re- the studythe study Investnvest igatoigato privacyivacy ananydd ost stringenst stringen necessary, necessa cords relevcords relev iver or authver or au InvestInve igatoiga st be approvt be app endments wndments ned beforened before mm the IRB/E the IRBmm tlle and ameand re do not ree do not re poses.poses. nstitutionnstitution anand Appd App e the e the start oart o submitted tubmitted t dates of issdates of iss sought. ought al"
69,page_69,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 69 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Celgene or its authorized represen tative. This documentation must also include a list of the members of the IRB/EC and their occupation and qualifications. If the IRB/EC will not disclose the names, occupations and qualifications of the committee members, it should be asked to issue a statement confirming that the composition of the committee is in accordance with GCP. For example, the IRB General Assurance Number may be accepted as a substitute for this list. Formal approval by the IRB/EC should mention the protocol title, number, amendment number (if applicable), study site (or region or area of jurisdiction, as applicable), and any other documents reviewed. It must mention the date on which the decision was made and must be officially signed by a commi ttee membe r. Before the first subject is enrolled in the study, all ethical and legal requirements must be met. The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol amendments in accordance with local legal requirements. Amendments must be evaluated to determine whether formal approval must be sought and whether the ICF should also be revised. The Investigator must keep a record of all comm unication with the IRB/EC and, if applicable, between a Coordinating Investigator and the IRB /EC. This statement also applies to any communication between the Investigator (or Coordinating Investigator, if applicable) and regulatory authorities. Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the IRB/EC prior to use. 13.7. Ongoing Information for Institutional Review Board/ Ethics Committee If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC: !Information on serious or unexpected adverse events as soon as possible; !Periodic reports on the progress of the study; !Deviations from the protocol or anything th at may involve added risk to subjects. 13.8. Termination of the Study Celgene reserves the right to terminate this st udy prematurely at any time for reasonable medical or administrative reasons. Any premature discontinuation will be appropriately documented according to local requirements (eg, IRB/EC, regulatory authorities, etc.). In addition, the Investigator or Celgene has the right to discontinue a single site at any time during the study for medical or administrative reasons such as: !Unsatisfactory enrollment; !GCP noncompliance; !Inaccurate or incomplete data collection; !Falsification of records; !Failure to adhere to the study protocol. CCI&(/*(1(35235,(7$5<,1)250$7,21otocol ocol aluated to aluated to also be revalso be rev and, if appand, if app o applies toapplie r, if applicar, if applic be reviewee revi onal Revienal Revie vestigator mestigator pected advepected adv gress of thegress of the otocolotoco or aorl of the Stuof the S ht to terminht to term ons. ons. Any pAny requirequi rereiiimenme e InvestInvest igaig studytudy ffyyor mor mff !!UnsatUnsat ii !!GG !"
70,page_70,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 70 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 201714. DATA HANDLING AND RECORDKEEPING 14.1. Data/Documents The Investigator must ensure that the records and documents pertaining to the conduct of the study and the distribution of the investigat ional product are complete, accurate, filed and retained. Examples of source documents include: hospital records; clinic and office charts; laboratory notes; memoranda; subjectâ€™s diaries or evaluation checklists; dispensing records; recorded data from automated instruments; copies or transcriptions certified after verification as being accurate copies; microfiche; x-ray film and re ports; and records kept at the pharmacy, and the laboratories, as well as copies of CRFs or compact disc, read only memory device (CD- ROM). 14.2. Data Management Data will be collected via CRF and entered into the clinical database per Celgene SOPs. This data will be electronically verified through use of programmed edit checks specified by the clinical team. Discrepancies in the data will be brought to the attention of the clinical team, and investigational site personnel, if necessary. Resolutions to these issues will be reflected in the database. An audit trail within the system will track all changes made to the data. 14.3. Record Retention Essential documents must be retained by the Investigator according to the period of time outlined in the clinical trial agreement. The Investigator must retain these documents for the time period described above or according to local laws or requirements, whichever is longer. Essential documents include, but are not limited to, the following: !Signed ICFs for all subjects; !Subject identification code list, screening log (if applicable), and enrollment log; !Record of all communications between the Investigator and the IRB/EC; !Composition of the IRB/EC; !Record of all communications between the Invest igator, Celgene, and their authorized representative(s); !List of Sub-investigators and other appropriately qualified persons to whom the Investigator has delegated significant study-related duties, together with their roles in the study, curriculum vitae, and their signatures; !Copies of CRFs (if paper) and of documentation of corrections for all subjects; !IP accountability records; !Record of any body fluids or tissue samples retained; !All other source documents (subject records, hospital records, laboratory records, etc.); CCI&(/*(1(35235,(7$5<,1)250$7,21s s , and and DD-- elgene SOPlgene SOP ks specifieds spec on of the clin of the cl sues will beues will made to thmade to th ator accordiator accord st retain thest retain th quirementsquirements follofollo wingwing de list, screee list, sc nicatinicati ons bons b he IRB/EChe IRB/E cocommuunin ative(s);tive(s); f Subf Sub -inveinv vestestigator higator thhe studye study !!Copiopie !!IPIP !"
71,page_71,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 71 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017!All other documents as listed in Section 8 of the ICH consolidated guideline on GCP (Essential Documents for the Conduct of a Clinical Trial). The Investigator must notify Celgene if he/she wishes to assign the essential documents to someone else, remove them to another location or is unable to retain them for a specified period. The Investigator must obtain approval in writi ng from Celgene prior to destruction of any records. If the Investigator is unable to meet this obligation, the Investigator must ask Celgene for permission to make alternative arrang ements. Details of these arrangements should be documented. All study documents should be made availabl e if required by relevant health authorities. Investigator or institution should take measures to prevent accidental or premature destruction of these documents. CCI&(/*(1(35235,(7$5<,1)250$7,21ruction of uction of"
72,page_72,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 72 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 201715. QUALITY CONTROL AND QUALITY ASSURANCE All aspects of the study will be carefully moni tored by Celgene or its authorized representative for compliance with applicable government regulations with respect to current GCP and SOPs. 15.1. Study Monitoring and Source Data Verification Celgene ensures that appropriate monitoring procedures are performed before, during and after the study. All aspects of the study are reviewed with the Investigator and the staff at a study initiation visit and/or at an Investigatorsâ€™ Meeting. Prior to enrolling subjects into the study, a Celgene representative will review the protoc ol, CRFs, procedures for obtaining informed consent, record keeping, and reporting of AEs/ SAEs with the Investigator. Monitoring will include on-site visits with the Investigat or and his/her staff as well as any appropriate communications by mail, email, fax, or telephone. During monitoring visits, the facilities, investigational product storage area, CRFs, subjectâ€™s source documents, and all other study documentation will be inspected/reviewed by the Ce lgene representative in accordance with the Study Monitoring Plan. Accuracy will be checked by performing source data verification that is a direct comparison of the entries made onto the CRFs against the appropriate source documentation. Any resulting discrepancies will be reviewed with the Investigator and/or his/her staff. Any necessary corrections will be made directly to the CRFs or via queries by the Investigator and/or his/her staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion criteria and documentation of SAEs and their proper recording be verified. Additional monitoring activities may be outlined in a study-specific monitoring plan. 15.2. Audits and Inspections In addition to the routine monitoring procedure s, a Good Clinical Practice Quality Assurance unit exists within Celgene. Representatives of this unit will conduct audits of clinical research activities in accordance with Celgene standard operating procedures (SOPs) to evaluate compliance with Good Clinical Practice guidelines and regulations. The Investigator is required to permit direct access to the facilities where the study took place, source documents, CRFs and applicable supporting records of study subject participation for audits and inspections by IRB/ECs, regulatory authorities (eg, FDA, European Medicines Agency [EMA], Health Canada) and company authorized representatives. The Investigator should make every effort to be available for the audits and/or inspections. If the Investigator is contacted by any regulatory aut hority regarding an in spection, he/she should contact Celgene immediately. CCI&(/*(1(35235,(7$5<,1)250$7,21a will will e e facilitcilities, ies, l other studother stu accordanceaccordanc t iis a dis a di recrecii cumentationumentatio /her staff. /her sta by tby the Invhe Inv nts, adherents, adhe ecording beecording b ecific mecific m onion cedures, cedures a GG atives of thatives of th ne e standardstandar Practice guPractice gu to permit dto permi and applicand app by IRB/by IRB ECC ealththl Canad Canadhh eryeryeffeffyyort toort tff anyany regulat regulayy lyy.."
73,page_73,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 73 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 201716. PUBLICATIONS As described in Section 13.2, all protocol- and amendment-related information, with the exception of the information provided by Celgene on public registry websites, is considered Celgene confidential information and is not to be used in any publications. Celgene protocol- related information proposed for use in a publication must be submitted to Celgene for review and approval, and should not be utilized in a publication without express written approval from Celgene, or as described in the Clinical Trial Agreement. Celgene will ensure Celgene-sponsored studies are considered for publication in the scientific literature in a peer-reviewed journal, irrespective of the results. At a minimum, this applies to results from all Phase 3 clinical studies, and a ny other study results of significant medical importance. This also includes results relating to investigational medicines whose development programs have been discontinued. Study results may also be presented at one or more medical congresses, and may be used for scientific exchange and teaching purposes. Additionally, this study and its results may be submitted for inclusion in all appropriate health authority study registries, as well as publication on health authority study registry websites, as required by local health authority regulations. Eligibility for external authorship, as well as selection of first authors hip, will be based on several considerations, including, but not limited to, contribution to protocol development, study recruitment, data quality, participation in data analysis, participation in study steering committee (when applicable) and contribution to abstract, presentation and/or publication development. CCI&(/*(1(35235,(7$5<,1)250$7,21es to s to al evelopmenevelopmen maymay byye usedused resulresul ts mts ml es, as well aes, as we h authorityh authority thorship, wthorship, w tion to protion to pro rticipation icipation tion and/ortion and/o"
74,page_74,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 74 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 201717. REFERENCES Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, et al. Relapse, rebound and psoriasis adverse events: An advisory group report. J Am Acad Dermatol. 2006;54:S171- 81. Chan CS, Van Voorhees AS, Lebwohl MG, Korman NJ, Young M, Bebo BF, et al. Treatment of severe scalp psoriasis: From the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;6:962-71. FDA Guidance for Industry E10. Choice of control group and related issues in clinical trials. May 2001. Feldman SR, Housman TS. Patientsâ€™ vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4(4):221-4. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-6. Griffiths, CE, Reich K, Lebwohl M, Kerkhof P, Paul C, Menter A, Cameron, GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials Lancet 2015; 386:541-51. Hogan DJ, Rooney ME. Facial telangiectasia associ ated with long-term a pplication of a topical corticosteroid to the scalp. J Am Acad Dermatol 1989;20:1129-30. Kimball AB, Luger T, Gottlieb A, Puig L, Kaufma nn R, Nikai E,et al. Impact of ix ekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. J Am Acad Dermatol. 2016;75(6):1156-61. Kragballe K, Menter A, Lebwohl M, Tebbey PW, van der Kerkhof PC. Long-term management of scalp psoriasis: perspectives from the Inte rnational Psoriasis Council. J Dermatol Treat. 2013;24:188-92. Lebwohl M. Psoriasis. Lancet. 2003a;361:1197-204. CCICCI CCICCI CCI &(/*(1(35235,(7$5<of P, Paul Cf P, Paul C OsuntokunOsuntokun ercept or plercept o : resulre ts fts flrrfff cicialaltelangitelanll p. J p. Am AmA T, Gottlieb , Gottlieb riitytyiii and and yy otot cad Dermacad Derm K, Menter K, Menter psoriasis: psoriasis: ;24:188;24:188 -92-97$5(7$ (/*&(&(I5<,1)250$7,21ent of nt o m Acad m Acad inical trialsnical trial treatments treatments simple pracmple prac 5<"
75,page_75,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 75 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Naegeli, AN, Flood, E, Tucker J, Devlen J, Edson-Heredia E. The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol 2015;54:715-22. Ortonne JP, Chimenti S, Luger T, Puig L, Reid F, Tr Ï‹eb RM. Scalp psoriasis: European consensus on grading and treatment algorithm. JEADV 2009;23:1435-44. Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, Augustin M, Szepietowski JC, StÃ¤nder S. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numeric rating scale and verbal ra ting scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012; 92:502-7. Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, Goldblum O, Dennehy EB, Kerr L, Sofen H. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2016 Nov 13:1-6. [Epub ahead of print] SAS Institute Inc. 2008. SAS/STAT Â®9.2 Userâ€™s Guide. Cary, NC: SAS Institute Inc. Szepietowski, JC, Reich, A. Itch-in Psoriasis Management. Curr Probl Dermatol. Basel, Karger, 2016;50:102-10. van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology. 1998;197:326-34. van der Vleuten CJ, van de Kerkhof PC. Management of scalp psoriasis: guidelines for corticosteroid use in combination treatment. Drugs. 2001;61:1593-8. Warren RB, Brown BC, Griffiths CE. Topical treatments for scalp psoriasis. Drugs. 2008;68:2293-302. CCICCItus.s ehy EB, hy EB, vere psoriasvere psoria VERVER --2,2, nstnstititute Incute r Probl DerProbl De Scalp psorScalp pso 326326-34.-34. ment of scalment of sca rugsugs..2001;2001 cal treatmecal treatme"
76,page_76,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 76 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 201718. APPENDICES Appendix A: Table of Abbreviations Table 6: Abbreviations and Specialist Terms Abbreviation or Specialist Term Explanation ADL Activity of daily life AE Adverse event ALT Alanine aminotransferase (SGPT) ANCOVA Analysis of covariance AST Aspartate aminotransferase (SGOT) ATC Anatomical Therapeutic Chemical BID Twice daily BMI Body mass index CI Confidence Interval CIN Cervical intraepithelial neoplasia CD-ROM Compact disc, read only memory device CIOMS Council for International Organization of Medical Sciences CMH test Cochran-Mantel-Haenzel test CO 2 Carbon dioxide CRO Contract Research Organization CRF Case report form CXR Chest radiograph DLQI Dermatology Life Quality Index EC Ethics Committee ECG Electrocardiogram eCRF Electronic case report form EMA European Medicines Agency EOT End of treatment FAS Full analysis set FCBP Females of childbearing potential FDA Food and Drug Administration CCICCI CCI&(FASFAS&(/*(1(35235,(7$5<,1)250$7,21777$7$7$7$70$5025)21),1<5<asiaasia$5memory dememory d7$ ional Organonal Organ(7 -Haenzel teHaenzel te5,xideide35ct t ReResearch rc23ase report fose report fo52Chest radiChest rad35(DerDem(((31(EE1(1((1((1*(/*OTOT(/&(&"
77,page_77,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 77 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Table 6: Abbreviations and Specialist Terms (Continued) Abbreviation or Specialist Term Explanation GCP Good Clinical Practice GI Gastrointestinal HDL High-density lipoproteins HIV Human immunodeficiency virus HPA Hypothalamic-pituitary-adrenal HRQoL Health-Related Quality of Life IB Investigatorâ€™s Brochure ICF Informed c onsent form ICH International Council for Harmonisation IL Interleukin IND Investigational New Drug IP Investigational product IRB Institutional Review Board IRT Interactive Response Technology ITT Intent-to-treat IUD Intrauterine device LDH Lactate dehydrogenase LLN Lower level of normal LOCF Last observation carried forward LS Least squares MedDRA Medical Dictionary for Regulatory Activities MI Multiple imputation NRI Non-responder imputation NRS Numeric Rating Scale PA Posterior to anterior PDE4 Phosphodiesterase type 4 PP Per protocol CCICCI CCICCI &(/*(1(35235,(7$5<,1)250$7,21777$7$7$7$70$5025)21),1 5<$57$ echnologyechnolog(7,( vicevice5 ehydrogenashydrogen23r level of nor level of n52Last observaast obser5 Least sqast 3(((1(1(1((1((1*(/* PAPA&(&&CI(("
78,page_78,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 78 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Table 6: Abbreviations and Specialist Terms (Continued) Abbreviation or Specialist Term Explanation PUVA Psoralens ultraviolet A RBC Red blood cell SAE Serious adverse event ScPGA Scalp Physician Global Assessment SGOT Serum glutamic oxaloacetic transaminase SGPT Serum glutamic pyruvic transaminase SMT Safety Management Team SOP Standard Operating Procedure SSC Scientific steering committee SUSAR Susp ected unexpected serious adverse reaction TB Tuberculosis TC Total cholesterol TEAE Treatment- emergent adverse event TNF Tumor necrosing factor TST (PPD) Tuberculin sensitivity test (purified protein derivative) ULN Upper limit of normal USA United States of America UV Ultraviolet UVB Ultraviolet B WBC White blood cell WHO World Health Organization CCICCI CCI CCI &(/*(1(352rculin sensitrculin sensi52Upper limit Upper lim5 United Sited3(UltrUlt(((1(1(1((1((1*( (/*235,(7$5<,1)250$7,21777$7$7$7$70$5025)21),1 5<dverse reactverse rea$57$(7 nt adverse ent adverse e,( ing factoring factor5 2323"
79,page_79,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 79 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix B: Scalp Physician Global Assessment (ScPGA) Score Category Description 0 ClearScalp Plaque Elevation = 0 (no elevation over normal skin) Scalp Scaling = 0 (no evidence of scaling) Scalp Erythema = 0 (except for residual hyperpigmentation/ hypopigmentation) 1 Almost ClearScalp Plaque Elevation = Â± (possible but difficult to ascertain whether there is a slight elevation above normal skin) Scalp Scaling = Â± (surface dryness with some desquamation) Scalp Erythema = Â± (faint, diffuse pink or slight red coloration) 2 MildScalp Plaque Elevation = slight (slight but definite elevation, typically edges are indistinct or sloped) Scalp Scaling = fine (fine scale partially or mostly covering lesions) Scalp Erythema = mild (light red coloration) 3 ModerateScalp Plaque Elevation = marked (marked definite elevation with rough or sloped edges) Scalp Scaling = coarser (coarser scale covering most or all of the lesions) Scalp Erythema = moderate (definite red coloration) 4 SevereScalp Plaque Elevation = marked (marked elevation typically with hard or sharp edges) Scalp Scaling = coarser (coarse, non tenacious scale predominates covering most or all of the lesions) Scalp Erythema = severe (very bright red coloration) CCI&(/*(1(35235,(7$= mmarked (marked (m arser (coarsarser (coars r all of the ler all of the l emama= se= 7$5<,1)250$7,21$7her he ation)ation)$7$7$7 evation, typevation, typ tly coveringtly coverin n)25 ked definiteked definite scale coveriscale coveri (definite red(definite red<, veve7$ 23"
80,page_80,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 80 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix C: Modified Whole Body Itch Numeric Rating Scale (NRS) Instruction: Please think about your whole body (including your scalp) when answering the question below. Please rate the itching severity due to your psori asis by circling the number that best describes your worst level of itching in the past 24 hours. 0 1 2 3 4 5 6 7 8 9 10 0 = No itching 10 = Worst itch imaginable Naegeli, 2015 . CCI&(/*(1(35235,(7$5<,1)250$7,21he e best describest descri 10 = Wo10 = W"
81,page_81,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 81 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix D: Scalp Itch Numeric Rating Scale (NRS) Please rate the itching severity of your scalp due to your psoriasis by circling the number that best describes your worst level of itching in the past 24 hours .     1R VFDOS LWFK :RUVW VFDOSLWFK LPDJLQDEOH CCI&(/*(1(35235,(7$5<,1)250$7,21hat t"
82,page_82,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 82 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017 CCICCI &(/*(1(35235,(7$5<,1)250$7,21&(/*(1(35235,(7$5<,1)250$7,21"
83,page_83,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 83 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017 CCICCI &(/*(1(35235,(7$5<,1)250$7,21250$7,"
84,page_84,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 84 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix F: The Dermatology Life Quality Index (DLQI) The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE LAST WEEK. Please check one box for each question. 2YHUWKHODVWZHHNKRZ itchy, sore, painful RUstinging KDV\RXU VNLQEHHQ""_ 9HU\PXFK _ $ORW _ $OLWWOH _ 1RWDWDOO 2YHUWKHODVWZHHNKRZ embarrassed RUself conscious KDYH \RXEHHQEHFDXVHRI\RXUVNLQ""_ 9HU\PXFK _ $ORW _ $OLWWOH _ 1RWDWDOO 2YHUWKHODVWZHHNKRZPXFKKDV\RXUVNLQLQWHUIHUHGZLWK\RX JRLQJ shopping RUORRNLQJDIWHU\RXU home RUyard""_ 9HU\PXFK _ $ORW _ $OLWWOH _ 1RWDWDOO _ 1RWUHOHYDQW 2YHUWKHODVWZHHNKRZPXFKKDV\RXUVNLQLQIOXHQFHGWKH clothes \RXZHDU""_ 9HU\PXFK _ $ORW _ $OLWWOH _ 1RWDWDOO _ 1RWUHOHYDQW 2YHUWKHODVWZHHNKRZPXFKKDV\RXUVNLQDIIHFWHGDQ\ social RUleisure DFWLYLWLHV""_ 9HU\PXFK _ $ORW _ $OLWWOH _ 1RWDWDOO _ 1RWUHOHYDQW 2YHUWKHODVWZHHNKRZPXFKKDV\RXUVNLQPDGHLWGLIILFXOWIR U \RXWRGRDQ\ sport""_ 9HU\PXFK _ $ORW _ $OLWWOH _ 1RWDWDOO _ 1RWUHOHYDQW 2YHUWKHODVWZHHNKDV\RXUVNLQSUHYHQWHG\RXIURP working RU studying""_ <HV _ 1R _ 1RWUHOHYDQW ,IÂ³1RÂ´RYHUWKHODVWZHHNKRZPXFKKDV\RXUVNLQEHHQD SUREOHPDW work RUstudying""_ $ORW _ $OLWWOH _1RW DWDOO CCI&(/*(1(35235,(7$5<,1)250$7,217,$777 $ORW$ORW RWDWDOORWDWDOO25 _ _ 9HU\PXF9HU\PX _ _ $OLWWOH$OLW<, GDQ\GDQ\ socialsocia(7$7$7$ \RXUVNLQPD\RXUVNLQPD23 KDV\RXUVNLQV\RXUVNLQ(3 RYHUWKHODVWZHUWKHODVW PDPWwork work RR (/"
85,page_85,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 85 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix F: Dermatology Life Quality Index (DLQI) (Continued) 2YHUWKHODVWZHHNKRZPXFKKDV\RXUVNLQFUHDWHGSUREOHPV ZLWK\RXU partner RUDQ\RI\RXU close friends RUrelatives""_ 9HU\PXFK _ $ORW _ $OLWWOH _ 1RWDWDOO _ 1RWUHOHYDQW 2YHUWKHODVWZHHNKRZPXFKKDV\RXUVNLQFDXVHGDQ\ sexual difficulties ""_ 9HU\PXFK _ $ORW _ $OLWWOH _ 1RWDWDOO _ 1RWUHOHYDQW 2YHUWKHODVWZHHNKRZPXFKRIDSUREOHPKDVWKH treatment IRU\RXUVNLQEHHQIRUH[DPSOHE\PDNLQJ\RXUKRPHPHVV\RU E\WDNLQJXSWLPH""_ 9HU\PXFK _ $ORW _ $OLWWOH _ 1RWDWDOO _ 1RWUHOHYDQW Finlay, 1994. CCI&(/*(1(35235,(7$5<,1)250$7,217, 1RWUHOHYDQW1RWUHOHYDQ 25"
86,page_86,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 86 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017 CCICCI 7,21 &(/*(1(35235,(7$5<,1)250$7,2"
87,page_87,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 87 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017 CCICCI 21 &(/*(1(35235,(7$5<,1)250$7,2"
88,page_88,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 88 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017 CCICCI 21 &(/*(1(35235,(7$5<,1)250$7,21"
89,page_89,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 89 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017 CCICCI 21 &(/*(1(35235,(7$5<,1)250$7,21"
90,page_90,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 90 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017 CCICCI &(/*(1(35235,(7$5<,1)250$7,21"
91,page_91,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 91 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017 CCICCI &(/*(1(35235,(7$5<,1)250$7,211)250$7,"
92,page_92,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 92 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017 CCICCI &(/*(1(35235,(7$5<,1)250$7,21$5<,1)250$7,2"
93,page_93,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 93 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017 CCICCI &(/*(1(35235,(7$5<,1)250$7,21(35235,(7$5<,1)250$7,21"
94,page_94,"EDMS Doc. Number: Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 94 CC-10004-SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix K: Treatment Schema for Dose Titration at Baseline Dose Day 1 Day 2 Day 3 Day 4 Day 5 Days 6 -7 Group AM PM AM PM AM PM AM PM AM PM AM PM Placebo (dummy titration)10 mg placebo + 20 mg placebo + 30 mg placebo10 mg placebo + 20 mg placebo + 30 mg placebo10 mg placebo + 20 mg placebo + 30 mg placebo10 mg placebo + 20 mg placebo + 30 mg placebo10 mg placebo + 20 mg placebo + 30 mg placebo10 mg placebo + 20 mg placebo + 30 mg placebo20 mg placebo + 30 mg placebo20 mg placebo + 30 mg placebo20 mg placebo + 30 mg placebo20 mg placebo + 30 mg placebo20 mg placebo + 30 mg placebo20 mg placebo + 30 mg placebo 30 mgapremilast(titration)10 mg apremilast + 20 mg placebo + 30 mg placebo10 mg placebo + 20 mg placebo + 30 mg placebo10 mg apremilast + 20 mg placebo + 30 mg placebo10 mg apremilast + 20 mg placebo + 30 mg placebo10 mg apremilas t + 20 mg placebo + 30 mg placebo10 mg placebo + 20 mg apremilast + 30 mg placebo20 mg apremilast + 30 mg placebo20 mg apremilast + 30 mg placebo20 mg apremilast + 30 mg placebo20 mg placebo + 30 mg apremilast20 mg placebo + 30 mg apremilast20 mg placebo + 30 mg apremilast CCI&(/*(1(35235,(7$5<,1)250$7,21e Corporae Corpora 21 priprietetDay 5Day 50$ MM PP55505 boo 0 mg mg placeboacebo20 mg 20 mg placebp + 3+ 32555 <1)5 st st mg mg aceboacebo20 mg 20 mg apremilast apremilast + 30 mg30 placeplace<<< 5,((7((5<"
95,page_95,"EDMS Doc. Number: Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 95 CC-10004-SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix L: Treatment Schema for Dose Titration at Week 16 Dose Day 112 Day 113 Day 114 Day 115 Day 116 Days 117 through 118 Group AM PM AM PM AM PM AM PM AM PM AM PM Placebo to 30 mg apremilast (titration)10 mg apremilas t + 20 mg placebo + 30 mg placebo10 mg placebo + 20 mg placebo + 30 mg placebo10 mg apremilast + 20 mg placebo + 30 mg placebo10 mg apremilast + 20 mg placebo + 30 mg placebo10 mg apremilast + 20 mg placebo + 30 mg placebo10 mg placebo + 20 mg apremilast + 30 mg placebo20 mg apremilast + 30 mg placebo20 mg apremilast + 30 mg placebo20 mg apremilast + 30 mg placebo20 mg placebo + 30 mg apremilast20 mg placebo + 30 mg apremilast20 mg placebo + 30 mg apremilast 30 mg apremilast (dummy titration) 10 mg placebo + 20 mg placebo + 30 mg apremilas t10 mg placebo + 20 mg placebo + 30 mg apremilast10 mg placebo + 20 mg placebo + 30 mg apremilast10 mg placebo + 20 mg placebo + 30 mg apremilast10 mg placebo + 20 mg placebo + 30 mg apremilast10 mg placebo + 20 mg placebo + 30 mg apremilast20 mg placebo + 30 mg apremilast20 mg placebo + 30 mg apremilast20 mg placebo + 30 mg apremilast20 mg placebo + 30 mg apremilast20 mg placebo + 30 mg apremilast20 mg placebo + 30 mg apremilast CCI&(/*(1(35235,(7$priprietetsts7$5g cebobo 30 mg 30 mg apremilastapremilast (7(7(7(7$5<,1)250$7,21e Corporae Corpora 21 Da$7$7$7$7 PMPM0$$$ 5$ bo0 mg m apremilast apremilast + 30 mg + 30 mg placebplac25550 ,125 20 mg20 m placpla +,1,11 $5,1"
96,page_96,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 96 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix M: Titration Blister Card Configuration CCI&(/*(1(35235,(7$5<,1)250$7,21"
97,page_97,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 97 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix N: Active Treatment Blister Card Configuration CCI&(/*(1(35235,(7$5<,1)250$7,21"
98,page_98,"EDMS Doc. Number:Apremilast Protocol CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 98 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix O: Placebo Treatment Blister Card Configuration CCI&(/*(1(35235,(7$5<,1)250$7,21"
99,page_99,"EDMS Doc. Number: Celgene Signing Page This is a representation of an electronic record that was signed electronically in Livelink. This page is the manifestation of the electronic signature(s) used in compliance with the organizations electronic signature policies and procedures. 8VHU1DPH  7LWOH 'DWH 6XQGD\'HFHPEHU 30(DVWHUQ'D\OLJKW7LP H 0HDQLQJ $SSURYHGQRFKDQJHVQHFHVVDU\ CCIPPD PPD &(/*(1(35235,(7$5<,1)250$7,21"
100,page_100,"EDMS Doc. Number:Apremilast Summary of Changes CC-10004-SPSO-001 Celgene Corporation Confidential and Propri etary 3 CC-10004- SPSO-001 Amendment 1 Final: 30 Nov 20171. JUSTIFICATION FOR AMENDMENT Changes included in this amendment are summarized below: !Modified Section 4.2 Inclusion Criteria 9 such that approved contraceptive options includes 2 options to reflect the standard contraception language for all Apremilast studies. !In Section 6.4 Efficacy Assessment: added inst ructional text to Scalp Physician Global Assessment to guide investigators on method of assessment. !Provided clarification to Section 6.5 Safety Assessment that subjects with positive TB testing at screening who have documentation of completed TB treatment w ill qualify for the study. This is in line with the Exclusion Criteria 8. !Modified Sections 9.2, 9.5, 11.1 a nd 11.2 by changing protocol violations to protocol deviations to reflect current sponsor standards. !Modified Section 8.2 Prohibited Concomitant Medications and Procedures: Topical therapy. Replaced acetylsalicylic acid with salicylic acid preparations. This is in line with Exclusion Criteria 17. !Provided updates to the following appendices to reflect the validated and IRB approved questionnaires that were provided to the subjects since the initiation of the study: oAppendix C: Modified Whole Body Itch Numeric Rating Scale; oAppendix D: Scalp Itch Numeric Rating Scale; oAppendix F: The Dermatology Life Quality Index; CCIC CI &(/*(1(35235,(7$5<,1)250$7,21TB TB ualifualifyyffffofor r ns to protocns to protoc oceduresocedur : aratiarations. ons. ThTh thhe evalidatva ce the initce the init iai NumNum eric Reric ing Scaleing Scale Life Qualitife Quali 35,(235"
